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INTRODUCTION 
For every woman in the world it is a joy to be pregnant and successfully carry their 
baby. A normal functioning thyroid is very essential for this, that helps the woman in 
their journey through pregnancy. For a healthcare personnel it is the joy of satisfaction 
in delivering a healthy mother and baby at the end of gestation. But unfortunately, if 
thyroid dysfunctions especially hypothyroidism are overlooked during early 
pregnancy, they can have adverse outcomes for both mother and foetus. 
 
In a woman during pregnant state, normally there are different physiological alteration 
of the pituitary-thyroid axis with an increase iodine metabolism.(1) These alteration 
lead to increase formation of thyroxine-binding globulin (TBG) and increase in total 
thyroid- hormone level. There is also increase in the level of thyroid stimulating 
hormone (TSH).  
 
In pregnancy, there is increased demand for the maternal thyroid hormones by the 
developing in utero foetus.(2) The early developing foetus, cannot produce its own 
thyroid hormones till about 12 weeks of gestation life. These maternal thyroid 
hormones are critically necessary during first trimester period for the essential normal 
neurodevelopment of the foetus. These requirements in pregnancy lead to increased 
demand on the maternal thyroid. It can lead to goitrogenic effect on the thyroid gland 
in some individual and cause thyroid dysfunction i.e. Hypothyroidism. 
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In the event of such thyroid dysfunction during pregnancy, the earlier the maternal 
thyroxine level is corrected the better is the outcome for the foetus.  
 
In an individual, sometimes the non-specific changes of hypothyroidism may be 
overlooked in non-pregnant state, which can lead to under diagnosis during 
pregnancy. In such cases, the untreated hypothyroidism can have adverse maternal 
outcome with significant perinatal morbidity. Some studies (3–5) have also shown 
that lack of thyroid hormone during 1st trimester foetal neuro development is 
associated with lower intelligence quotient (IQ) and poor cognition of the off springs. 
Thus, clinical hypothyroidism directly or indirectly, also through its association with 
other comorbidities affects both mother and foetus.  
Therefore, it is necessary that hypothyroidism should be detected early in pregnancy 
and promptly initiated with treatment. If a pregnant woman is already a known case of 
hypothyroidism, then proper titration of the thyroid medications in early pregnancy is 
very important. 
 
Our study was designed to provide an opportunity to evaluate the outcome of 
pregnancy in hypothyroid mothers and compare it with those without hypothyroidism 
in the population catered by our Institution. In this study we would also study the 
various perspectives about the screening for hypothyroidism in pregnancy. 
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Aim and Objective of the Study: 
 
Aim:  
To compare the Obstetric and Perinatal outcomes in pregnant women with 
hypothyroidism versus those without in a tertiary care hospital in South India. 
 
 
Objectives of study:  
(1) To see if there is any difference in the incidence of adverse maternal and 
neonatal outcomes in pregnant women with hypothyroidism as compared to 
those without. 
 
(2) To determine whether routine screening for thyroid disorder should be offered 
to all pregnant women. 
 
 
 
12 
 
 
REVIEW OF LITERATURE 
Thyroid is one of the important endocrine gland of our body. It secretes 
triiodothyronine (T3), thyroxine (T4) and a calcium regulating hormone, the 
calcitonin. These hormones play very important role in maintaining the normal body 
metabolism and calcium homeostasis for the normal psychosexual development. (6) 
 
Thyroid dysfunction especially hypothyroidism is the most common endocrine 
disorder in the population of the world. It is also a major concern for women during 
pregnancy as such thyroid disorder are related with adverse maternal and perinatal 
outcomes.(7) (8) (9) 
 
The literature describes that most common cause of overt hypothyroidism (OH) in 
pregnancy is chronic autoimmune thyroiditis. It is also known as Hashimoto’s 
thyroiditis. Other causes leading to hypothyroidism are endemic iodine deficiency (in 
certain geographical areas), and in women who had prior therapy with radioactive 
iodine.(10,11) 
 
Hyperthyroidism is seen very rarely. It is estimated that  in about only 0.1-0.4% of 
pregnant women have this thyroid dysfunction.(12) 
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 During the pregnancy, a woman’s body undergoes different varied physiological and 
hormonal changes. Such changes lead to the high thyroid hormone demand from the 
thyroid gland. If the gland is unable to replenish such growing need it can lead to 
hypothyroidism.  
The clinical signs of hypothyroidism may be overlooked in pregnancy as its clinical 
signs and symptoms can be masked by the hypermetabolic state of pregnancy.(12) 
(13) In these cases, if hypothyroidism  is not detected by the clinician and treated, 
later it can have adverse effects on both maternal and foetal outcomes.(10) (9)  
 
The current scientific data suggests that mothers with untreated maternal 
hypothyroidism during the state of pregnancy, are associated with various adverse 
outcomes. The studies show these mothers can have miscarriages, recurrent pregnancy 
loss (RPL), abruptio placentae, pre-eclampsia, gestational diabetes (GDM), 
postpartum haemorrhage (PPH), increase chance of caesarean sections (LSCS), 
congestive cardiac failure (CCF) and rarely have myopathy in mothers.(10) (14–16) 
  
In some recent studies, they have shown that untreated hypothyroidism in the mother 
can also affect the perinatal outcome. It could lead to preterm deliveries, intrauterine 
growth restriction (IUGR), intrauterine foetal death (IUFD), respiratory distress and 
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high perinatal mortality rates. It is also associated with new-borns who have poor 
cognitive functions, neurological and developmental impairment.(10,17) 
 
Prevalence in pregnancy: 
 The prevalence of thyroid disorder in women during pregnancy as quoted in western 
literature is about 2.5 %. In this about 0.3-0.5% of women have overt hypothyroidism 
(OH) and about 2-2.5% of pregnant women are subclinical hypothyroidism (SCH). 
(10,18) (19) 
The prevalence data as per our Indian literature, in comparison showed that the 
prevalence of hypothyroidism among the pregnant women in India was about 4.8-
11%.(2) (20)  
 
 A large study by Sahu et al 2010 have reported prevalence rate of hypothyroidism in 
pregnant women was 6.47%. Out of which 4.58% cases had overt 
hypothyroidism.(21) 
Another study by Ajmani et al, (2014) from India, showed that prevalence rate of 
hypothyroidism among the Indian pregnant women was 12%. In these hypothyroid 
women, 3% were overt hypothyroid (OH) & 9% were sub clinical hypothyroid (SCH). 
The thyroid peroxidase antibodies (TPO) positivity was seen in 50% of the study 
pregnant women with subclinical hypothyroidism and 7% of the euthyroid pregnant 
women.(22) 
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Anatomy of the thyroid gland  
The thyroid gland is a brownish-red coloured endocrine gland found in front of the 
neck over the trachea. It spans across from the level of 5th cervical vertebrae to 1st 
thoracic vertebrae.  
The gland is butterfly in shape and consist of two lateral lobes with pair of superior 
and inferior poles. The two-lateral thyroid lobes are about 5-6 cm long and are 
connected by isthmus of height about 12-15 mm. The intervening isthmus overlies 
traches from second to fourth tracheal rings. (Figure 1) (23,24) 
 
                                             Figure 1 The thyroid gland anatomy 
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The thyroid gland weighs about average 25-30 g in adults and can be slightly more 
heavier in women.(25) 
 The thyroid gland in women usually enlarges in size during menstruation and 
pregnancy. 
The gland has a conical lobe which arises from the isthmus or in some cases from the 
adjacent lobe (more often from left lobe) toward the hyoid bone. This lobe is called as 
the Pyramidal lobe. In some individuals, it may be attached by a fibrous or 
fibromuscular band to the hyoid bone.  
In few instances there may be the remnants of the embryological thyroglossal duct. It 
can persist either as an accessory nodules or cysts within the thyroid tissue, between 
the isthmus and foramen caecum of the base of tongue. There are also two pairs of 
parathyroid glands lying in close proximity of the gland tissue. 
 
Histological structure of thyroid gland 
The thyroid gland lies in between the middle layer of deep cervical fascia. It is 
enclosed by a true inner capsule, which is very thin and closely adheres on the outer 
gland surface. This capsule sends many extensions within the substance of the gland 
and forming numerous septae. These septae thus divide the gland into lobes and 
lobules.  
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These lobules are made up of many follicles which forms the main structural units of 
the gland. These thyroid follicles are made up of a layer of simple epithelium which 
encloses a colloid-filled cavity.  
On viewing through microscope this colloid appears homogenous pink in colour on 
Haematoxylin and Eosin [H&E] stains. (Slide 1) 
 
 
Slide 1: H&E stain slide of thyroid showing colloid filled normal follicles of gland. 
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The central colloid which contains the main iodinated glycoprotein, known as iodo 
thyroglobulin. This glycoprotein is the principal precursor of the later formed active 
thyroid hormones (T3 &T4) 
These follicles may vary in size inside the gland. When the gland is stimulated, these 
follicular cells turn columnar and lumen gets depleted of colloid.  
 
When the thyroid gland function is suppressed, the follicular cells turn flat with 
colloid accumulation in the lumen. These follicles are also surrounded by network of 
dense plexuses made up of fenestrated capillaries, lymphatics and sympathetic nerves. 
There are also Parafollicular cells, which lie adjacent to the follicles within the basal 
lamina. 
 
The epithelial cells of thyroid gland, are made up of two types of cells i.e.(i) 
 principal cells (or the follicular cells) and (ii) parafollicular cells (or the C cells).  
 
The principal cells have main function is to form colloid (iodothyroglobulin), whereas 
the parafollicular cells form calcitonin, the main hormone central to the calcium 
homeostasis in our body. 
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Biosynthesis of Thyroid hormone in thyroid 
The thyroid gland is responsible to produce 2 biologically active hormones, which are 
Thyroxine (T4) and 3,5,3'-triiodothyronine (T3).  The two hormones fundamentally 
differ in their structure. The Thyroxine hormone has 2 Iodine atoms on its phenyl 
(outer) ring but T3 hormone has only 1 Iodine atom.  
 
Thyroxine is solely produced by the thyroid gland, whereas T3 is produce not only in 
thyroid but also in many other peripheral tissues by the process of deiodination of 
Thyroxine. 
 
                                        Figure:2 Various thyroid hormone structure. 
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The thyroid hormone synthesis occurs in the thyroid gland by following 
steps:(26)  (as shown below in Figure 3) 
 
 
                   
                       Figure 3: Thyroid Hormone Synthesis Mechanism 
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(a)  Dietary Iodide transport to thyroid:(27) 
The iodine present in our diet is absorbed in iodide or the ionic form. It is rapidly 
absorbed and distributed in the body’s extracellular fluid (ECF) compartment. 
The biosynthesis of thyroid hormones requires large amount of Iodine. 
 
 Iodide from the ECF is actively transported into thyroid follicular cells against a 
chemical & electrical gradient by the sodium iodine transporter. It is a 
transmembrane protein situated on the membrane of thyroid follicular cells. This 
process leads to the relative high concentration of Iodide presence in the thyroid 
gland as compared to the rest of the body. 
 
   (b) Thyroglobulin Synthesis in the follicle: 
        Thyroglobulin is a 660 kilodalton (kd) glycoprotein protein made up of many 
amino acids as tyrosine. It is biosynthesized and then glycosylated in the rough 
endoplasmic reticulum (RER) of the follicular epithelial cell.  
 
In the follicle cells, tyrosine residues are iodinated and coupled to form T4 and T3 and 
released into the follicular lumen. The thyroglobulin protein is made up of 6 
molecules of mono iodotyrosine (MIT), 4 molecules of di iodotyrosine (DIT), 2 of T4 
& 0.2 of T3 per molecule. 
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  (c) Tyrosyl iodination:(27) 
      Thyroid peroxidase is a very important enzyme present in the colloid of the 
follicular cell lumen. It helps to forms I2 by oxidizing I- ions and then "organifies" the 
generated I2 by covalently linking it with tyrosine residues of the Thyroglobulin.  
This thus leads to formation of either single or double-iodinated forms of tyrosine 
amino acid known as "Monoiodotyrosine (MIT)" and "Diiodotyrosine (DIT)". 
 
       Coupling of iodotyrosyl residues of thyroglobulin 
 The enzyme thyroid peroxidase helps in coupling of these MIT and DIT residues to 
generate T4 or T3 hormone within the thyroglobulin. Thyroxine hormone is thus 
formed by combination of two DIT residues while T3 is formed by combination of 
one DIT with one MIT residue.  
Thyroid peroxidase can combine 2 DIT residues and form T4 more readily, hence 
thyroid gland is site for primarily producing T4 rather than T3. 
 This enzyme also helps catalyse iodination of 10% of tyrosine residues of 
thyroglobulin 
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   (d)  Endocytosis of Peroxidase-processed Thyroglobulin and hormone release: 
        The peroxidase-processed thyroglobulin is endocytosed by follicular epithelial 
cells which fuses with lysosomes to form phagolysosomes. In these phagolysosomes 
the thyroglobulin is hydrolysed to T4, T3, and its other amino acids.  
Whenever the thyroid gland is stimulated these formed thyroid hormones are released 
into the circulation.  
This peroxidase-processed thyroglobulin within the follicle act as reservoir for thyroid 
hormones. This is the reason why the defects of thyroid hormone often take months to 
become clinically apparent after gland dysfunction. 
 
    (e) Recycle of iodide: 
The iodotyrosines which are released from the thyroglobulin are deiodinated by the 
help of iodotyrosine deiodinase enzyme. Thus, most of the iodide is recycled for 
thyroid hormone synthesis again.        
 
Extrathyroidal T3 hormone production  
Approximately 80% of T3 hormone is produced at the extrathyroidal tissue. The 
process occurs by 5'-deiodination (outer-ring deiodination) of Thyroxine 
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This reaction takes place with the help of two, plasma membrane and microsomal 
enzymes i.e. T4-5'-deiodinases (type I) and T4-5'-deiodinases (type II). These 
enzymes are present in abundant amount in liver and kidney. These organs are the 
major sources of T3 hormone. 
Both enzymes T4-5'-deiodinase (types I and II) are very different in location, 
biochemical properties and functioning to physiologic stimuli 
●Enzyme Type I T4-5'-deiodinase:  It is the main deiodinising enzyme present in the 
liver, kidney, and thyroid. It is also Propylthiouracil(PTU) sensitive. The 35% of the 
extra thyroidally produced T3 is contributed by this enzyme. 
●Enzyme Type II T4-5'-deiodinase: It is the main deiodinising enzyme present in 
muscle, brain, pituitary, skin, and placenta. It is not inhibited by PTU. The 65% of the 
extra thyroidally produced T3 is contributed by this enzyme. 
The proportion varies in thyroid dysfunction. Type II enzyme contributes higher in 
hypothyroidism and lower in hyperthyroidism.                    
 
Regulation of thyroid hormone: (as shown in Figure 4) 
The Thyroid hormone level in body is regulated by 2 pathways as follows: 
1) The thyroidal hormone biosynthesis with secretion of thyroxine and 
triiodothyronine (T3) is regulated by thyroid-stimulating hormone (TSH). The 
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secretion of TSH is inhibited by high T4 & T3 and stimulated by thyrotropin-
releasing hormone (TRH). 
 
2) The extrathyroidal conversion of Thyroxine to T3 is usually regulated by diet, 
hormonal and disease-related factors.  
 
 
 
Figure: 4 Regulation of Thyroid hormones 
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The thyrotropin releasing hormone (TRH) is secreted by Hypothalamus, whose 
stimulation leads to the secretion of thyroid stimulating hormone (TSH). TRH is a 
tripeptide made up of pyroglutamyl-histidyl-prolineamide found mainly in the median 
eminence and paraventricular nuclei of hypothalamus. It is responsible for the TSH 
secretion via receptor-mediated activation of PCP pathway. 
TSH is made and secreted by the thyrotropes present in the anterior pituitary gland. It 
is secreted in the blood and reaches its target organ i.e. thyroid. In thyroid gland it 
stimulates the production and secretion of T3 and Thyroxine hormone. TSH 
biochemically is a glycoprotein made up of alpha and beta subunits containing about 
15% carbohydrate.  
The normal TSH physiological secretion is pulsatile and its secretion is 50 to 100 
percent higher in the late evening than the daytime. The normal TSH secretion rate in 
individual ranges from 75 to 150 mU/day. 
The high level of T3 and Thyroxine causes feedback inhibition of TSH, both directly 
and indirectly by suppressing the release of hypothalamic TRH. The inhibition of TSH 
synthesis occurs by inhibition of transcription of TSH subunit genes. 
Thyroxine is usually converted to T3 in liver and many other extra thyroid tissues by 
the action of T4 monodeiodinases. 
 Some Thyroxine and T3 is conjugated with glucuronide and sulfate in the liver, 
excreted in the bile and some hydrolyzed in the intestine and excreted. The T4 and T3 
in the intestine may be reabsorbed in small amounts. (Figure 4) 
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Mechanism of action of TSH on the thyroid gland 
TSH stimulation is very essential in thyroid hormone biosynthesis and secretion by 
the thyroid gland. Its stimulation leads to expression of genes in thyroid tissue causing 
thyroid enlargement. 
The specific actions of TSH occurs by binding to its specific trans membrane 
receptors. This activates the enzyme adenylyl cyclase which increases the cyclic AMP 
formation in the cell. This process causes the activation of several protein kinases. 
TSH also stimulates the phospholipase C enzyme activity thus increasing 
phosphoinositide turnover, increasing intracellular calcium ion concentration and also 
the protein kinase C activity.  
The mechanism how these changes are link to specific steps of hormone formation is 
not known. 
 
Exogenous agents altering normal TSH secretion 
These agents are glucocorticoids, somatostatin infusion and dopamine infusion. 
• Glucocorticoids cause decrease in the pulsatile TSH secretion by inhibiting the 
TRH secretion.  
• Somatostatin infusion or its analog Octreotide reduce serum TSH 
concentrations.  
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• Dopamine infusion causes a rapid decrease in serum TSH concentrations in the 
body at doses of 1 mcg/kg per min and more. That is why the serum TSH 
concentrations of intensive care unit patients on dopamine have low TSH.  
 
Alternatively.it is also seen that TSH levels rise after the administration of 
dopamine antagonists such as metoclopramide. These agents act directly on the 
pituitary gland to cause inhibition. Dopamine is also a physiologically 
important agent causing inhibition of TSH secretion in body. 
 
The inhibitory effects of these exogenous agents are clinically small.  
While high secretion of endogenous dopamine, somatostatin, or glucocorticoid may 
transiently decrease TSH levels. Their sustained increases in production do not cause 
reduction of TSH or hypothyroidism.  
 
Physiological changes in thyroid metabolism in pregnancy 
In a pregnant woman there is an increased metabolic demand in body and also from 
the developing foetus. This changes lead to significant changes in the thyroid 
physiology.(28) (12) It is influenced by two important maternal hormones which are 
human chorionic gonadotrophin (HCG) and oestrogen hormone. (13,28) 
 
29 
 
To meet this increase in demand during pregnancy, thyroid gland function increases 
by 10% but in areas of iodine deficiency its function can double i.e. increase by about 
20-40%.(29) This causes thyroid gland to increase in size by 15% during pregnancy 
which later returns to normal after delivery.(11)  
 
The principal normal variations of thyroid gland function during pregnancy 
are:(11,12) 
(a)  Increase in level of serum thyroxine-binding globulin (TBG) –  
In early phase of first trimester pregnancy the serum TBG levels double i.e. 
increases to almost two times under the influence of circulating maternal 
estrogen hormone. Increase estrogen causes TBG production and TBG 
sialylation in the body. 
 This leads to reduced hepatic clearance of TBG from the blood.  
This excess TBG level causes increase of extra thyroidal pool of serum total T4 
and T3 level.  
 
So, to maintain the adequate free thyroid hormone circulation, thyroxine (T4) 
and triiodothyronine (T3) production by the thyroid gland is increased.  
Thus, there is an increase in levels of total T4 and T3 by about 50% during the 
first half of pregnancy and it plateaus at approximately 20 weeks of gestational 
age. 
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(b)  Stimulation of thyroid-stimulating hormone [TSH]) receptor by human 
chorionic gonadotropin (hCG) –  
 
Human chorionic gonadotropin (hCG) and TSH hormone belong to the same 
family of glycoprotein hormones and have common alpha subunit with a 
unique beta subunit. Hence, hCG hormone tend to have a weak TSH like 
activity in the body. In laboratory study by human thyroid cell culture assay, it 
was found that about 1 microU of hCG was equivalent to about 0.0013 microU 
of TSH. 
 
 Normally the serum hCG concentrations increase soon after fertilization and 
peak at 10 to 12 weeks which also causes the increases in total serum T4 and 
T3 concentrations.  
This physiological subclinical hyperthyroidism is transient. Later as the 
pregnancy progresses the hCG secretion declines and serum free T4 and T3 
levels also decline and consequently serum TSH level rises slightly. 
 
Effect of pregnancy on urinary Iodine excretion from body:(13) 
In addition to above physiological changes in thyroid gland during pregnancy there is 
also an increase in urinary iodine excretion. This phenomenon occurs due to high 
glomerular filtration rate during pregnancy as well as due to increased plasma 
clearance of iodine. This further leads to decrease in iodine stores of the body. 
However, in women who have borderline or deficient iodine reserve, there is fall in 
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circulating thyroid hormone level. This causes hypothyroidism and leading to increase 
in thyroid stimulating hormone.  
 
Trimester specific TSH reference ranges- (10) 
As mentioned, the thyroid gland undergoes important physiological adaptation during 
pregnancy with changes in size and function. The TSH level during pregnancy is 
lower as compared to the non-pregnant state. Hence, it is recommended to use 
population based trimester specific reference ranges as follows.  
First trimester TSH range: 0.1 – 2.5mIU/ml 
Second trimester TSH range: 0.2 – 3.0mIU/ml 
Third trimester TSH range: 0.3 – 3.0mIU/ml. 
 
Definitions: 
Primary maternal hypothyroidism is a clinical condition defined as the presence of 
elevated Thyroid Stimulating Hormone (TSH) levels as per trimester during 
pregnancy. 
Primary hypothyroidism is of two types either Overt Hypothyroidism (OH) or 
Subclinical Hypothyroidism (SCH) in pregnant women.  
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Subclinical hypothyroidism is diagnosed clinically in a pregnant women when 
serum TSH level is between 2.5-10 mIU/L (in first trimester) and between 3-10 mIU/l 
(in second/third trimester) with normal T4 levels. (10) 
 
Overt hypothyroidism is diagnosed in a pregnant women when the serum TSH level 
is >2.5millil U/l in first trimester (>3.0 mIU/l in second/third trimester) with raised T4 
levels and/or Serum TSH >10mIU/L irrespective of T4 level. (10) 
 
Autoimmune thyroid disease 
 It is chronic autoimmune thyroiditis or also known as Hashimoto's thyroiditis. It was 
first described by Hashimoto in 1912, in patients with goitre showing intense 
lymphocytic infiltration of the thyroid gland described as “struma lymphomatosa”  
This condition leads to thyroid failure in 10% of a population. It is the most frequent 
cause of hypothyroidism seen in iodine-sufficient areas of the world.   
The condition cause gradual thyroid failure, with or without thyroid enlargement. It 
occurs more commonly in women with male to female ratio of 1:7. The estimated 
incidence rate is about 5-20% (30) 
 
It is an autoimmune-mediated condition in which destruction of the gland occurs by 
apoptosis of the thyroid epithelial cells. The characteristic histopathological feature 
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consists of dense lymphocytic infiltration, with lymphoid germinal centres, and 
destruction of thyroid follicles (Slide 2).  There are areas of fibrosis and areas of 
follicular-cell hyperplasia induced by thyroid-stimulating hormone (TSH). There is 
intrathyroidal lymphocytic infiltration of both T and B lymphocytes types.   
 
 
Slide 2 Hashimoto thyroiditis 
Clinically it is of two types: 
• Atrophic thyroiditis which results primarily because of the cell-mediated 
cytotoxicity causing follicular cell apoptosis and complement-dependent 
antibody-mediated cytotoxicity leading to thyroid damage. The presence of 
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TSH receptor blocking antibodies results in loss of gland morphological 
integrity, which may be reversible. 
 
• Goitrous thyroiditis resulting by one of three mechanisms (i) lymphocytic and 
plasma cell infiltration, (ii) production of antibodies that stimulate thyroid 
enlargement, (iii) excess TSH secretion. 
 
 
In this condition hypothyroidism is the characteristic functional abnormality but there 
can be transient hyperthyroidism referred as Hashitoxicosis. 
The chief pathology consists of presence of various antibodies and antigen-specific T 
cells directed towards thyroid antigens, leading to chronic autoimmune thyroiditis. 
The major known thyroid antigens are: 
●Thyroglobulin  
●Thyroid peroxidase (TPO) 
●Thyroid-stimulating hormone (TSH) receptor 
 
Impact of Autoimmune thyroid disease on pregnancy 
The study by Thangaratinam et al.2011 (31) had shown that presence of various 
thyroid autoantibodies in euthyroid pregnant women had significant risk for 
unexplained subfertility, miscarriage, recurrent miscarriage, preterm birth and 
maternal postpartum thyroiditis. The detection of thyroid antibodies in early 
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pregnancy can lead to chance of developing post-partum thyroiditis in 33-50% of 
cases. (32) 
A systematic review and meta-analysis was done restricted to thyroid autoimmunity 
done on two very small studies.  It showed that treatment with levothyroxine lowers 
the risk for miscarriage and preterm birth. The other effects of treatment on pregnancy 
complications or subfertility, or the effect were not studied in this review.(31,33) 
A recent study showed that pregnant women with thyroid peroxidase antibody have 
higher depression, anger and postpartum mood disturbances regardless of risk of 
developing postpartum thyroiditis.(32) 
At present there is no guidelines or available treatment for the women diagnosed with 
thyroid autoantibodies. However, serum TSH should be monitored to identify the 
development of hypothyroidism later. (34)  The Cochrane review found no benefit on 
outcome of pre-eclampsia when treated with levothyroxine in pregnant women in 
euthyroid state with TPO positive but there was reduction of miscarriages and pre 
term. (32) 
 
Thyroid peroxidase (TPO) Antibodies 
In pregnant women while doing thyroid function test, TPO antibodies is also done. 
The assessment of antibody status is important in pregnancy. The study suggest that 
women with subclinical hypothyroidism and positive anti-thyroid peroxidase (TPO) 
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antibodies tend to have more risk of adverse pregnancy outcomes at a lower TSH level 
than in women with negative TPO antibodies. (33) 
As per the American Thyroid Association (ATA) systematic review (ATA guidelines 
on thyroid disease during pregnancy) suggest that the risk of pregnancy-specific 
complications was apparent more in TPO-positive women with about TSH >2.5 mU/L 
but was not consistently apparent in TPO-negative women until TSH values exceeded 
5 to 10 mU/L. 
In another study it was revealed that euthyroid women with  high thyroid peroxidase 
antibody (TPO) concentrations  have increased risk of foetal loss, perinatal mortality 
and have large for gestational age babies.(35)  
These pregnant women also have more risk of developing subclinical hypothyroidism 
in first trimester and thyroiditis in the postpartum period. 
But still in euthyroid women with positive TPO antibodies whether to monitor for 
development of hypothyroidism or to treat with levothyroxine is still a controversy. 
Though some studies reveal that treatment with levothyroxine may improve the 
miscarriage rate in such cases further trials are still waited for management guidelines 
in this regard. 
 
Post-partum thyroiditis 
It is a type of destructive thyroiditis caused by an autoimmune process which occurs 
within a span of one year after delivery. The global prevalence ranges from 1 to 17%. 
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(36) The mean prevalence in the general population was approximately 7 to 8 % of 
women.(36)  
 
A higher prevalence rate of about 25% is seen certain women group who have either 
type 1 diabetes mellitus, had prior history of postpartum thyroiditis and if women has 
positive anti thyroid peroxidase antibodies (TPO). 
It usually presents in the following three ways: 
●Transient hyperthyroidism only 
●Transient hypothyroidism only 
●Transient hyperthyroidism followed by hypothyroidism and then recovery. 
 
Clinical feature 
The cause is not known. The affected women present in postpartum period with 
mildly enlarged, diffuse, nontender thyroid gland and abnormal thyroid function 
which disappears with recovery.  It presents in one to four months post-delivery and 
lasts two to eight weeks. It has phase of hyperthyroidism followed by hypothyroidism, 
which lasts from approximately two weeks to six months, and then full recovery. 
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Pathology: 
In the thyroiditis phase, thyroid gland has lymphocytic infiltration with occasional 
germinal centres with disruption and collapse of thyroid follicles. Usually, fine-needle 
aspiration biopsies reveal lymphocytes, thyroid follicular cells, and masses of colloid. 
In phase of recovery it reveals presence of lymphocytic infiltration and some fibrosis 
but the thyroid follicles are normal. 
 
Treatment of Post-partum thyroiditis 
Majority of women require no treatment for either Hyperthyroid or Hypothyroid phase 
of the illness but their thyroid function should be monitored. 
Women who have bothersome symptoms in hyperthyroid phase require treatment with 
beta adrenergic antagonist drug. Women who are breastfeeding, propranolol is 
preferred drug of choice. 
Women in hypothyroid phase with TSH >10m IU/L require initiation of levothyroxine 
therapy with monitoring of TSH level. 
In 30 % of cases, women don’t recover from the hypothyroid phase and require long 
term levothyroxine therapy. (37) 
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Isolated maternal hypothyroxinaemia (IMH) 
Till present still a proper consensus regarding the definition of IMH is lacking in 
scientific literature. 
As per 2011 American Thyroid Association’s clinical guidelines on the management 
of thyroid disease in pregnancy, it defines IMH as a normal trimester wise maternal 
TSH  with FT4 in the lower 5th or 10th percentile.  (38) 
The prevalence of IMH in the population as per the study literature ranges from 1.3 to 
23.9%. (39,40)  This  prevalence of IMH is found to be higher among the women 
residing in countries who still have severe iodine deficiency. 
 
Causes of IMH 
The real cause of IMH is still not known clearly. Studies suggest that there are many 
factors which may be associated with this entity.  The various causative factor which 
can lead to IMH are iodine deficiency (most common), high BMI (obesity), iron 
deficiency, and imbalance between pro and anti-angiogenic factors. 
 
Impact of Maternal Hypothyroxinaemia 
The FASTER Trial, a National Institute of Child Health and Human Development–
sponsored study (Oct.1999-Dec.2002) (41)  the study documented hypothyroxinaemia 
in 2.1% in first and 2.3% in the second trimester. This study showed that 
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hypothyroxinaemia during the first trimester was related with preterm labour 
(adjusted odds ratio 1.62; 95% confidence interval 1.00–2.62) and macrosomia (aOR 
1.97; 95% CI 1.37–2.83) and in the second trimester, it was associated with 
gestational diabetes (aOR 1.7; 95% CI 1.02–2.84). The study suggested that the 
effects of IMH are trimester dependent. In this study the author has not perform 
conditional analyses and so the results are inconsistent. Hence, the results of this study 
need to be interpreted with caution. 
 
In a study done by Pop VJ et al. (4)  on infants and toddlers born to mothers with low 
free thyroxine with normal TSH during 12 to 24 weeks of gestation. The study reveals 
that children born to such mothers had lower mean intelligence, psychomotor or 
behavioural scores as compared to women with normal thyroid function during 
gestation.   
However, there is still need for further evaluation with a sufficiently powered RCT on 
the treatment management of IMH early in pregnancy and evaluate whether IMH 
should be treated or not. 
 
Role of Iodine in Hypothyroidism: 
India is a vast country with population living in certain pockets like hilly region and 
foothills where iodine deficiency is still prevalent. (10) Pregnancy in a woman is a 
41 
 
state of increase thyroid hormone production requiring iodine replenishment for the 
proper thyroid functioning.  
 
The thyroid gland requires approximately 52 mcg of iodide normally to synthesize 
adequate amounts of Thyroxine hormone daily. 
 
Dietary iodine is absorbed rapidly as iodide and distributed in the extracellular fluid to 
reach thyroid gland. Iodine can be obtained by eating foods that naturally contain it as 
fish, seafood, kelp, some drinking water and vegetables grown in iodine-sufficient 
soil. Cow's milk is also a source of iodine as it also consumes iodine from its cattle 
feed. 
 Pregnant women have higher dietary iodine requirement than non-pregnant women 
because of increased thyroid hormone production, increased renal iodine excretion, 
and foetal iodine requirements.  
 
It is found that severe iodine deficiency in mother during pregnancy can result in low 
thyroid hormone production leading to primary hypothyroidism. This condition can 
lead to inadequate placental transfer of maternal thyroxine hormone to foetus in utero 
causing impaired foetal neurologic development. (42) 
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The World Health Organisation has recommended 250mcg of iodine in diet daily 
during pregnancy and lactation.  
 
Classification of Iodine status:(43) 
A system is derived for classifying the status of iodine deficiency and sufficiency, 
based on the median urinary iodine concentration in a population. 
Iodine sufficiency: defined as a median urinary iodine concentration of: 
●100 to 299 mcg/L in children and nonpregnant adults. 
●150 to 249 mcg/L in pregnant women. 
 
         Iodine deficiency: defined as median urinary iodine concentrations of- 
●Mild deficiency:           50 to 99 mcg/L 
●Moderate deficiency:   20 to 49 mcg/L 
●Severe deficiency:         <20 mcg/L 
 
A median average daily iodine intake of 150 mcg corresponds to median urinary 
iodine concentration of 100 mcg/L. 
In addition, the following factors can also exacerbate the effects of iodine deficiency 
such as coexistent iron deficiency, selenium deficiency, and vitamin A deficiency. The 
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ingestion of some foods such as cassava or millet containing goitrogenic substances 
can lead to hypothyroidism. 
 
 Thyroid hormone and the foetus: 
The developing foetus in utero till about 12 weeks of gestation is not capable of 
synthesizing its own thyroid hormone and is dependent on the mother for its supply of 
thyroid hormone. At about 10th to 12th week of gestation is when the foetal TSH 
starts to appears and the foetal thyroid begins to concentrate iodine and start 
synthesizing iodothyronines. (11,13) 
 
However, this small amount of hormone synthesis occurs until 18th to 20th week and 
then gradually the foetal thyroid secretion increases. 
As pregnancy reaches term the foetal serum T4, T3, and TSH concentrations differ 
substantially from the mothers. The foetal thyroid blood profile shows serum TSH 
levels are higher, serum free T4 concentrations are lower, and serum T3 
concentrations are one-half those of the mothers.  
 
After delivery, at birth, the serum TSH level increases rapidly from 50 to 80 mIU/L 
and then decreases to about 15mIU/L within 48 hours. The serum T3 and T4 
concentrations also rapidly rises higher than normal adults. 
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The amount of maternal thyroid hormones crossing the placenta is not known but 
evidence suggests that there is significant transfer of maternal thyroid hormones 
across the placenta. (44,45)  
Maternal thyroid hormones are very essential during the growth and development of 
foetal brain in the first trimester, when the foetus itself has no functional thyroid. 
Thyroid hormone helps in foetal brain differentiation, synaptogenesis, dendrite 
growth, axon myelination and neuronal migration. (9) The thyroid hormone works 
primarily through the TH receptors which are broadly dispersed in foetal brain tissue. 
(9) 
 It is also known that maternal TSH-receptor antibodies can cross the placenta and 
cause either foetal hyperthyroidism or hypothyroidism (46)  . Hence, such maternal 
thyroid disorder adversely affects not only the mother but also the neurodevelopment 
of the foetus in utero. 
 
Consequences of hypothyroidism on pregnancy: 
Dave et al (13) had conducted study which showed risk of miscarriages was 
significantly higher in pregnant women with hypothyroidism (71.4%) as compared to 
those without (28%).(17)  They also found  statistically significant difference in the 
occurrence of adverse perinatal outcomes in pregnant women with hypothyroidism 
than those without (46% vs 7.2%).The incidence of hypothyroidism among the 
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women with recurrent pregnancy loss {RPL} (i.e. up to 12 weeks GA) was 4.1-
16.6%.(47)  
 
Other studies have also shown that maternal OH has been associated with increased 
risk of preterm births, low birth weight (LBW) babies and miscarriages. (15,16) 
 
Sahu M et al. have similarly found in Indian population an increased risk of 
spontaneous miscarriage, gestational hypertension, anaemia, placental abruption and 
postpartum haemorrhage (PPH) in pregnant women with untreated 
hypothyroidism.(21) They also suggest that hypothyroid pregnant women can have 
increased risk of intrauterine growth restriction(IUGR) , intrauterine demise (IUD) 
and caesarean deliveries for foetal distress. The miscarriage rate among the subclinical 
hypothyroid was 12 -21% and in OH was 21%. (21) 
 
The Indian data shows stillbirth rate of 0-16.6% among subclinical hypothyroid while 
4.2% for OH. The incidence of pre-eclampsia reported among OH was 16% and 22% 
for SCH. (10)Similarly it shows the incidence of abruptio placentae is 16% in OH but 
only 5% among the subclinical hypothyroid. The intrauterine Growth Restriction 
(IUGR) prevalence rate for OH was 25% while 8% in subclinical hypothyroid and 
incidence rate were pre-term delivery was 33% among OH and 11% in the subclinical 
hypothyroid group.(10) 
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Complications of hypothyroidism in pregnancy 
Hypothyroidism if untreated can have adverse effects on the pregnancy outcomes.  
Depending upon the severity of the biochemical thyroid function test abnormalities, it 
can be classified to two types: 
●Overt hypothyroidism       or    
●Subclinical hypothyroidism 
 
Overt hypothyroidism   
In this type of thyroid dysfunction, the pregnant women present with clinical 
symptoms of hypothyroidism with blood test showing elevated TSH and decreased 
free T4. Usually this type is uncommon because of following two factors which 
contribute to the low number of pregnancy in these women-(48) 
1) These hypothyroid women are anovulatory. 
2) Overt Hypothyroidism (new or inadequately treated) is associated with 
increased rate of first trimester spontaneous abortion. 
 
 
Impact on pregnancy outcome of Overt hypothyroidism:(15) 
In continuing pregnancy in overt hypothyroidism, it is associated with various risks of 
complications as mentioned: 
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(I) Maternal - 
●Preeclampsia and gestational hypertension 
●Anaemia 
●Placental abruption 
●Postpartum haemorrhage 
●Preterm delivery, including very preterm delivery (before 32 weeks) 
●Increased rate of caesarean section 
(II) Foetal: 
●Non-reassuring foetal heart rate trace 
●Low birth weight (due to preterm delivery for preeclampsia)  
●Perinatal morbidity and mortality 
●Neuropsychological and cognitive impairment of child 
 
Impact on pregnancy outcome of Subclinical hypothyroidism  
In this type of thyroid dysfunction, the pregnant women have no clinical 
sign/symptoms of hypothyroidism at presentation. It is diagnosed only by impaired 
thyroid function on blood testing.  
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In subclinical hypothyroidism the blood examination reveals elevated TSH with a 
normal free T4. This is more common than overt hypothyroidism and is the most 
frequently occurring thyroid disorder in pregnancy.(12) 
 
Impact of subclinical hypothyroidism in pregnancy outcome 
The studies suggest that the risk of complications during pregnancy is lower in women 
with subclinical, than with overt hypothyroidism. (49) 
However, some studies show that women with subclinical hypothyroidism have 
increased risk for severe preeclampsia, preterm delivery, placental abruption, and/or 
pregnancy loss as compared with the euthyroid women.(50) 
A study by Liu H et al. (31) suggests that in women who have subclinical 
hypothyroidism with positive anti-thyroid peroxidase (TPO) antibodies tend to have 
more risk of adverse pregnancy outcomes occurring at lower TSH value than in 
hypothyroid women without TPO antibodies.  
 
Impact of subclinical hypothyroidism on children 
At this stage, it is uncertain to suggest that children of subclinical hypothyroid mother 
are at risk for neuropsychological impairment.(3) Though some observational studies 
suggest that it can be associated with impaired development of cognition in children. 
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Some expert argue that neurocognitive dysfunction of the children of women with 
subclinical hypothyroidism could be due to preterm delivery.(49) 
 
Management strategy for hypothyroidism in pregnancy 
• Controversy in screening strategies in pregnancy: Universal vs high risk 
approach  
 
Screening is a strategy used to identify the possible presence of an as-yet-undiagnosed 
disease in individuals without signs or symptoms. 
Universal screening involves screening of all individuals in a certain category. 
High risk or selective screening is conducted among risk populations only. 
 
There is still ongoing widespread controversy regarding the necessity of universal 
screening of thyroid function in pregnant women. The clinician need guidelines in an 
effort to reduce the adverse effect of thyroid dysfunctions and minimize risk of 
intellectual impairment in the off springs. 
Guidelines from the American Association of Clinical Endocrinologists and the 
American Thyroid Association (2012) do not recommend universal screening but to 
screen only women at risk. The Society of Maternal Foetal Medicine made similar 
recommendations in 2012.(51) 
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Moreover, the American College of Obstetricians and Gynaecologists (ACOG) in 
2015 recommended thyroid testing in pregnant women only  if they were 
symptomatic, or had personal history of thyroid disease or other medical disorders 
such as Diabetes Mellitus.(52)  
Cochrane collaboration in 2010 commented that “until more convincing data becomes 
available, only pregnant women at risk for thyroid disease should be tested”.(53) 
 
The Indian Thyroid Society (ITS) recommends screening of TSH levels in all 
pregnant women at the time of their first visit, ideally during pre-pregnancy evaluation 
or as soon as pregnancy is confirmed. 
Due to the conflicting results in support of universal screening for hypothyroidism in 
pregnancy, it is not recommended by different societies. However, at present, in view 
of insufficient data to support universal TSH screening for thyroid dysfunction, the 
high-risk approach is followed. 
 
As per the latest “2017 Guidelines of the American Thyroid Association for the 
Diagnosis and Management of Thyroid Disease during Pregnancy and the 
Postpartum” (54) which suggests: 
- The role of Universally screening of thyroid dysfunction during pregnancy remains 
controversial at present. 
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- There is still insufficient data to recommend for or against universal screening for 
TSH in early pregnancy. 
 
- Any screening for detecting low FT4 concentrations in pregnant women is not 
recommended. 
-It strongly recommends that all pregnant women be verbally screened at the initial 
prenatal visit for any history of thyroid dysfunction, and prior or current use of either 
thyroid hormone or antithyroid medications. 
 
-If pregnant women has any of the following risk factors, then testing for serum TSH 
is recommended:(54) 
 
1. A history suggestive of hypothyroidism/hyperthyroidism or current 
symptoms/signs of thyroid dysfunction 
2. Previous known thyroid antibody positivity or goitre present. 
3. Any prior history of head or neck radiation or thyroid surgery 
4. Age >30 years 
5. Type 1 diabetes or autoimmune disorders 
6. Past history of pregnancy loss, preterm delivery, or infertility 
7. Multiple prior pregnancies (≥2) 
8. Family history of autoimmune thyroid disease or thyroid dysfunction 
9. Morbid obesity (BMI ≥40 kg/m2) 
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10. Use of amiodarone or lithium, or recent administration of iodinated radiologic 
contrast 
11. Resident of area with moderate to severe iodine insufficiency. 
 
Treatment of hypothyroidism in pregnancy 
Levothyroxine is the only drug of choice for treatment of hypothyroidism. It is a 
category A, FDA approved drug and safe for use in pregnancy. Levothyroxine is 
easily available for treatment as ‘levothyroxine sodium’ in the form of oral tablets of 
different strengths as 25mcgm, 50mcgm, 100mcgm. It is available in moisture proof 
brown glass bottles and should be stored at room temperature.  
The patient is advised to avoid direct exposure of medication to sunlight at all times. 
The prescribed dose of the medication should be taken empty stomach in the morning 
regularly. The patient is also advised not to take any food for at least half hour of 
eating levothyroxine. 
If dose is missed on one day it is recommended that patient takes levothyroxine as 
soon as she remembers it and avoid eating for the next half hour. 
If patient forgets to take medicine for one day then patient is advised to take double 
dose the next morning. 
The medication has no contraindications. 
In the prescribed recommended dosage levothyroxine has no side effects. 
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The studies have shown that early treatment of overt hypothyroidism (OH) with 
levothyroxine helps in reduction of adverse perinatal outcomes and highly 
recommended. The goal of treatment of oral levothyroxine is to attain trimester 
specific TSH levels. (10) 
The pregnant women who had subclinical hypothyroidism should also be initiated on 
treatment with levothyroxine and studies have shown that they are less likely to 
develop eclampsia, pre-eclampsia, miscarriages, placental abnormalities, preterm 
births and low birth weight babies as compared to the untreated group. 
The treatment goal is to attain target TSH in the lower half of the trimester-specific 
reference range as mentioned. When this is not available, then it is reasonable to target 
maternal TSH concentrations below 2.5 mU/L. 
 
 Justification of our present study 
The evidence from present medical literature is currently based on small observational 
studies or those which are retrospective in nature with very few prospective ones.  
Also, the result of studies is conflicting with some showing association with adverse 
maternal and perinatal outcome whereas others do not. 
There is still controversy regarding the Universal or high-risk screening in the 
pregnant women and we hope to find clinical evidence for our catering population for 
betterment of our health services.  
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MATERIALS AND METHODS 
 
Research design: A prospective cohort study was done in Christian Medical College 
and Hospital Vellore, India. 
 
Study period: November 2016 to August 2017 
 
Study Setting:  
Study cohort was selected prospectively from pregnant women attending the antenatal 
clinic and/or endocrine clinic of Christian Medical College. 
 
The research proposal was presented before the Institutional Review Board of 
Christian Medical College and Hospital, Vellore and approved prior to the recruitment 
of cases. 
 
Participants: 
 
Group 1: The pregnant women with known hypothyroidism or those diagnosed to 
have hypothyroidism at <20 weeks gestation were enrolled into Group 1 if they met 
the inclusion criteria and willing to participate in the study. These participants were 
treated for hypothyroidism as per Endocrine protocol. 
 
Group 2: Pregnant women with normal TSH and willing to participate in our study 
were enrolled. 
 
INCLUSION CRITERIA: 
 
 (1) All women with singleton pregnancy who were known hypothyroidism prior to 
pregnancy. 
(2) Diagnosed to have hypothyroidism in less than 20 weeks gestation in current 
pregnancy. 
(3) Agreed to delivery at our hospital. 
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EXCLUSION CRITERIA:   
 
Pregnancies with   (1) Multiple gestations 
                               (2) Chronic Hypertension 
                                (3) Pregestational diabetes (DM) 
                                (4) Participants not willing for delivery at our Hospital.  
 
The pregnant women attending antenatal clinic in our hospital were invited for our 
study. All patients were explained about the nature of our study. Informed consent 
was obtained from each participant of both the Group 1 and 2. 
 
The women who were previously hypothyroid on treatment or were diagnosed for the 
first time during pregnancy, if they met the inclusion criteria and were willing to 
participate in our study were recruited as Group 1.  
 
Of these women, who were previously Hypothyroid prior to pregnancy, in their first 
visit for ANC check-up, their serum TSH was done. The trimester wise cut off was 
taken i.e. first trimester TSH <2.5 m IU/L and second trimester TSH <3 m IU/L and 
their thyroid medication dose was titrated as per the Endocrine protocol. 
 
The women were followed every 4-6 weeks with TSH, till delivery. Target TSH was 
to maintained its level < 3m IU/L in second and third trimesters.  
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These women after delivery in post-partum period were advised to start pre-pregnancy 
dose of Levothyroxine and continue follow up in Endocrinology department with 
serum TSH and TFT levels after 4-6 weeks.  
 
The women diagnosed as subclinical or overt hypothyroidism during pregnancy were 
also enrolled in Group 1. The trimester wise cut off for TSH was evaluated and they 
were started on oral Levothyroxine as per the Endocrine protocol.  
These women were also followed with TSH every 4-6 weeks and trimester wise TSH 
based, thyroxine dose was adjusted according to Endocrine protocol.  
 
The pregnant women, visiting our antenatal clinic with normal thyroid function 
(confirmed by a blood test) who met the inclusion criteria and were willing to 
participate in the study were enrolled as Group 2 with prior taking informed consent. 
The pregnant women of both the groups were followed as per our study protocol till 
delivery. In the postpartum period details were recorded. The new born baby details 
were also obtained from the neonatal charts post-delivery.            
 
Reason for ordering TFTs in pregnancy:  
                    1) Symptomatic 
                                             2) Increased BMI (>40 Kg/m2) 
                                                           3) Recurrent 1st Trimester miscarriages 
                                                                    4) Infertility 
                                                          5) Family history of Thyroid disorder 
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                                                       6) History of head or neck radiation 
                                                                     7) Coming from area of Iodine deficiency 
                                                                      8)Type 1 Diabetes       
 
                                                                      
Variables: 
 
Subclinical hypothyroidism was diagnosed when serum TSH levels were between 2.5-
10 mIU/L (in first trimester) and between 3-10 mIU/l in second trimester with normal 
T4 levels.  
 
Overt hypothyroidism was diagnosed when serum TSH levels >2.5mIU/l in first 
trimester (>3.0 mIU/l in second trimester) with raised T4 levels and/or Serum TSH 
>10mIU/L in any trimester irrespective of T4 level. 
 
 
 
Primary Maternal Outcomes: - Hypertensive disorders in Pregnancy. 
 
(a) Gestational Hypertension: Blood pressure 140/90mmHg or more found for 
the first time after 20 weeks of pregnancy without proteinuria. And returned 
to normal within 12 weeks post-partum. 
 
 
(b) Pre-eclampsia was defined as BP >= 140/90 mm Hg with significant urine 
albumin or urine protein creatinine ratio >0.3. 
 
 
 
(c) Eclampsia was defined as presence of generalized tonic clonic convulsions 
in women with pre-eclampsia in absence of other neurological conditions. 
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Secondary maternal outcomes: 
 
(a) Spontaneous Miscarriage: Loss of foetus <22week of gestation or foetal 
weight 500gms after ruling out other causes of miscarriage. 
 
 
     (b)      Anaemia:  Haemoglobin <11gm/dl in first trimester/ third trimester. 
                                      - Haemoglobin <10.5gm/dl in second trimester.     
  
     (c)      Gestational Diabetes: defined as fasting plasma glucose between 92-126 
mg/dl in first trimester or an abnormal glucose tolerance test at 22-26 weeks of 
pregnancy. 
 
 
(d) Transverse uterotomy for delivery of the foetus. 
  
 
 
Primary Neonatal Outcomes: - 
 
(a) Low Birth weight: defined as birth weight less than 2.5kg. 
 
 
Secondary Neonatal outcomes: - 
 
(a) Prematurity: defined as birth at less than 37 weeks of gestation. 
 
(b) Intrauterine demise (IUD): defined as death of a foetus in utero at 24 weeks 
of pregnancy or foetus weighing >500gms. 
 
 
(c) Intrauterine growth restriction (IUGR): defined as birth weight < 10th 
centile as per gestation age. 
 
    (d)        Neonatal Hypothyroidism: defined as increased cord TSH >25 m IU/L. *  
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*In new born infants if cord TSH is found to be >25m IU/L then thyroid function test 
(TFT) is done after 72hrs. If found to be abnormal then started on thyroid replacement 
therapy for lifelong. The infants are followed in Neonatology Department at 3month, 
6month and 1 year with regular TFT. 
Sample size 
The sample size was calculated using n Master 2.0 software. To test the significant 
difference in gestational hypertension (GHTN) and low birth weight (LBW) among 
pregnant women with hypothyroidism and in pregnant women with normal thyroid 
function.  
The required number of samples is calculated as below: {reference (7)(28)} 
Two Proportion - Hypothesis Testing - Large Proportion - Equal Allocation 
 GHTN LBW 
Proportion in Group 1   0.36 0.56 
 Proportion in Group 2 0.2 0.2 
Estimated risk difference  0.16 0.36 
Power (1- beta) % 80 80 
Alpha error (%) 5 5 
1 or 2 sided  2 2 
Required sample size for each arm  122 27 
 
No. of participants in Group 1 = 125 
No. of Participants in Group 2 = 125 
Total sample size of the study is N=250. 
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Bias:  Bias is not an issue in our study since occurrence of maternal and/or neonatal 
complications could not be modified in either group. 
 
Diagrammatic Algorithm of the study 
 
 
SUBCLINICAL HYPOTHYROIDISM TSH   >2.5-3 <10 with normal T4 
OVERT HYPOTHYROIDISM TSH>10 m IU/L or >2.5-3 and <10 with abnormal T4 
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(Note: If TSH is abnormal in women with no risk factor then complete TFT is done 
prior recruiting her to Group 1.) 
 
 
 
 
 
BOTH GROUP 1 AND 
GROUP 2
ROUTINE ANTENATAL 
AND INTRAPARTUM CARE
FOLLOW UP POST 
DELIVERY
MATERNAL OUTCOME
PRIMARY OUTCOME
Hypertensive disorder of 
Pregnancy
SECONDARY OUTCOME
Spontaneous miscarriage
Anaemia
Gestational Diabetes
Caeseraean Section
NEONATAL 
OUTCOME
PRIMARY OUTCOME
Low birth weight
SECONDARY OUTCOME
Prematurity
IUD
NICU admission
Neonatal Hypothyroidism
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BIOCHEMICAL ANALYSIS OF SAMPLES IN BRIEF: 
 
The blood for estimation of serum TSH was collected from the patient at booking 
along with routine antenatal bloods and was sent to the biochemistry lab.  
The TSH3-UL assay is performed by fully automated Advia Centaur XP analyser 
(Siemens Healthcare Diagnostics, Munich, Germany) in our laboratory.  
Advil Centaur XP uses the direct chemiluminescent principle.  
Advia Centaur XP assay uses dimethyl form of acridinium ester as the 
chemiluminescent label. 
 
The Advia Centaur XP “TSH3-UL assay” is type of two-site sandwich immunoassay 
which uses direct chemiluminometric technology. In this process, the first antibody is 
the Lite reagent. This is a monoclonal mouse anti-TSH antibody labelled with 
acridinium ester. The second antibody, in the Solid Phase, is a polyclonal sheep anti-
TSH antibody. It is covalently coupled to the paramagnetic particles. 
 
The Advia Centaur TSH assay is very efficient and sensitive. It can measure the 
hormone TSH concentration up to 150 mIU/L with a minimum detectable 
concentration (analytical sensitivity) of 0.004 mIU/L. 
The reference range is from 0.3 to 4.5 mIU/L 
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STATISTICAL ANALYSIS 
 
The data entry was done by using Epidata software and analysed using MS Excel and 
SPSS package. The baseline characteristics and foetal and neonatal outcomes of both 
the study groups were analysed using descriptive statistics and frequencies.  
 
For normally distributed continuous variables mean, SD and range were used and for 
non-normal continuous variables, median and IQR were used for variable description. 
The continuous variables were represented using histogram plot, while categorical 
variables were presented in simple bar charts, cluster bar charts and pie charts.  
 
The foetal and neonatal outcomes in group 1 and group 2 of categorical variable types 
were compared using either by Chi-square test or Fisher’s exact test. The continuous 
variables were compared using Independent samples t test or Mann-Whitney U test 
based on the normality assumption. The normality was decided based on histogram 
plot. p value <0.05 was considered as statistically significant. 
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STATISTICAL FORMULA USED 
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RESULTS 
 
In our study, a total of 250 pregnant women fulfilling the inclusion criteria were 
recruited who were willing to participate from the antenatal clinic of our hospital. And 
they were divided into Group 1 and Group 2. 
Group 1 = 127 (n)  
Pregnant women who were known cases of hypothyroidism prior to pregnancy or 
diagnosed for the first time during pregnancy. 
Group 2 = 123 (N)  
Pregnant women with normal thyroid function tests at booking. 
 
In Group 1, out of 127 women, 68 (53.5%) were known cases of hypothyroidism prior 
to pregnancy and were on medication. Among the known case of hypothyroidism n= 
68, 49 women had overt and 19 women had subclinical hypothyroidism respectively 
(Fig.1).  
In Group 1, the rest 59 women (46.4%) out of 127 were diagnosed to have 
hypothyroidism during pregnancy. Out of these 71.2% (n=42) were diagnosed in first 
trimester and 28.8% (n=17) were diagnosed in second trimester for hypothyroidism. 
(Fig.2) 
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Figure 1: Percentage of subclinical and overt disease among known cases of 
hypothyroidism in Group 1  
 
 
 
                 
 
There were no cases of overt hypothyroidism among those diagnosed during 
pregnancy. 
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Figure.2 Percentage of Cases of Hypothyroidism diagnosed during pregnancy in first 
trimester and second trimester in Group 1 
 
 
 
 
The median gestational   age at diagnosis was 12 weeks. (IQR 10-16) 
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Figure 3: Reasons for ordering Thyroid function tests in pregnant women  
 
 
                    
    
 
The most common indication for ordering TFTs during pregnancy was history of 
subfertility (n= 28) followed by presence of symptoms (n=15) and in 12 cases were 
picked up during routine investigations in pregnancy outside (Fig 3). 
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Figure 4.  Values of serum TSH (mIu/L) in Group 1 
 
 
 
 
Median TSH value was found to be 5.6 mIu/L with inter quartile range (IQR) being 4.5-
7.6   
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Figure 5 Duration of disease in years in known hypothyroid cases in Group 1 
 
 
 
Median duration of disease was 3 years with IQR (2-6 years). In four cases, duration of 
disease was not known by the patients 
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Figure 6: Dose of Thyroxine in pregnant women with hypothyroidism in Group 1 
 
 
 
Median dose of Levothyroxine in pregnant women with prior known hypothyroidism 
was 75 micrograms with IQR (50-100) in comparison to that in women diagnosed to 
have hypothyroidism during pregnancy where the dose was 50 micrograms with IQR 
(25-50). Among the women who were on medications, 43 (33.8%) required alteration 
(increased) in dose of medication.  There were none in whom the dose required to be 
reduced. 
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MATERNAL CHARACTERISTICS                                              
Table 1 Maternal Characteristics 
 
Maternal 
characteristics 
 
Group1 
n=127 
Group2  
N=123 
     p value 
Age (years) Mean+/- 
SD 
 
27.5 +/-4.1 25.1 +/-4.4 <0.001* 
BMI (Kg/m2); Mean 
+/-SD 
 
28.1+/-4.4 25.1+/-4.1 <0.001**` 
 
          Parity 
 
   
Primigravida (n, %) 
 
64 (51.2 %) 68 (54.4 %)  
 
0.789 (both) 
Multigravida (n, %) 
 
61 (48.8 %) 57 (45.6 %)  
 
 
Bad obstetric H/O 
(N, %)  
n=37(29.1%) N=26 (21.1%) 0.145 
 Previous abortion  17(45.9%)  9(7.2%) 0.369 
Previous Neonatal 
death 
3(8.1%) 3(11.5%) 0.983 
Previous abortion and 
Neonatal  
17(45.9%) 14(53.8%) 0.537 
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The maternal characteristics were similar in both groups in terms of age, Parity, and bad 
obstetric H/O (Table1).  
Although there was statistically significant difference in the ages of pregnant women in 
both the groups with older women being found more in group 1, this could be explained 
by the large sample size we had and this difference may not be clinically significant. 
Heavier women were found in group1 as compared to group 2, and this difference was 
statistically significant (p value <0.001). This could be explained by the fact that 
hypothyroidism occurs more in heavier women. 
In Group 1 had 37 pregnant women (29.1%) had previous bad obstetrics history, of 
which 45.9 % (n=17) had abortion,8.1 %(n=3) had neonatal death and 45.9% (n=17) 
had history of previous abortion and neonatal death. In Group 2 ,26 pregnant women 
(21.1 %) had previous bad obstetrics history, of which 07.2% (N=9) had abortion,11.5% 
(N=3) had previous neonatal death and 53.8% (N=14) had both previous abortion and 
neonatal death. Among both Groups previous abortion was clinically high in Group 1 
(45.9%) as compared with Group 2 (7.2%) but was not statically significant. (Table 1) 
and (Fig.10). 
Among 250 pregnant women, three had comorbid medical condition of Bronchial 
Asthma and all of these were from Group 2. 
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Figure 7: Distribution of ages of pregnant women in both groups                           
. 
 
 
 
 
 Majority of pregnant women recruited in both groups were in age group 20-29 years. 
(Fig.7)  
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Figure 8. Distribution of BMI of pregnant women in both the groups. 
 
 
 
    
 
 Majority of pregnant women in both groups were under BMI 26-30 kg/m2. More 
women in Group 1 had higher BMI than group 2 (p value <0.001). This is because 
women with hypothyroidism are known to be obese. 
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                                               Figure 9. Parity of women in both groups. 
 
 
 
 
 
Majority of pregnant women in both Group 1 and Group 2 were primigravida as 
compared with multigravida. 
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Figure 10: Occurrence of bad obstetric history in both groups. 
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TABLE 2: MATERNAL OUTCOMES IN BOTH GROUPS 
 
                 
OUTCOMES 
 
GROUP 1(n=127) GROUP 2 (N=123) p VALUE 
Hypertensive 
disorders 
 
19(15%) 
 
4(3.3%) 
 
0.001* 
Anaemia 
 
33(26%) 21(17.1%) 0.087 
Preterm Labour 
 
7 (5.5%) 11 (8.8%) 0.294 
Gestational diabetes 
 
36 (28.3%) 24 (19.5%) 0.102 
LSCS 
 
45 (35.4%) 39 (31.7%) 0.533 
*significant p value  
 
Occurrence of hypertensive disorders was significantly more in Group 1as compared to 
Group 2 with p value (.001). Although, anaemia and gestational diabetes were seen 
more often in Group 1, the difference between the two groups was not statically 
significant. The incidence of LSCS   was similar in both the groups (Table 2). There 
were no cases of miscarriage (threatened/spontaneous) or postpartum haemorrhage in 
either group.  
. 
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TABLE 3: NEONATAL OUTCOMES IN BOTH GROUPS 
 
 NEONATAL 
OUTCOMES 
GROUP 1 (n=127)  
 
GROUP 2 (N=123)   p*VALUE   
Gestational age at 
delivery <37 weeks 
(preterm birth) 
               
 
12 (9.4%) 
 
 
11 (8.9%) 
 
 
0.890 
Birth weight at 
delivery<2.5 kg 
(LBW) 
 
 
19 (15.0%) 
 
 
16 (13.0%) 
 
 
 
0.656 
Cord TSH 
>25 mIU/dl 
 
 
4 (3.1%) 
 
0 
 
0.122 
Foetal Growth 
Restriction 
 
 
17 (13.4%) 
 
18 (14.6%) 
 
0.776 
Neonatal Jaundice 1 (0.8%) 
 
 
6 (4.9%) 0.063 
NICU Admission 26 (20.4%) 12 (9.7%) 0.018 
Neonatal death 1 (0.8%) 0 >0.999 
 
Although there were significantly more number of cases of hypertensive disorders in 
Group1 in comparison to group2, the effects of this was not reflected in the neonatal 
outcomes since there was no difference in the incidence of foetal growth restriction  
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and Low birth weight between the two groups (Table 3) This can be explained by the 
fact that; most cases of hypertension were mild to moderate gestational hypertension. 
There was no significant difference in the occurrence of severe gestational hypertension 
or pre-eclampsia in both the groups.  
 
More babies from Group 1 had NICU admission than Group 2 (p value 0.018). Reasons 
were admission to NICU have been depicted in Figure 11. 
 
Out of 250 babies,4 had elevated cord TSH. All four of them belonged to group1. One 
baby from Group1 had early neonatal death due to severe asphyxia. The parturient had 
rupture uterus following labour induction and baby was severely depressed at birth with 
cord pH 6. 
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Figure 11.  Causes of NICU admission 
 
 
 
 
NICU admission were significant in Group 1. 
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Figure 12: REASONS FOR NICU ADMISSION IN GROUP 1. 
 
 
 
Most common cause for admission to NICU in Group1 babies has been classified as 
others. (27%, n=7) (Figure 12). Out of 7, three babies had bilateral hydronephrosis; two 
had transient tachypnoea of the new born; one baby had patent ductus arteriosus and 
one was diagnosed to have microcephaly. 
More Babies born to women with overt hypothyroidism required NICU admission for 
sepsis / jaundice/, hypoglycaemia. However, statistical significance could not be 
calculated due to small numbers. 
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Figure:13 MODE OF DELIVERY IN BOTH GROUPS 
 
 
 
 
The mode of delivery of pregnant women in both the groups were comparable. There 
was no statistical difference in the LSCS rates of women between both the groups.  (p 
value 0.533) (Table 1) 
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TABLE 4: COMPARISON OF MATERNAL AND NEONATAL OUTCOMES 
AMONG KNOW CASE OF HYPOTHYROID WOMEN WITH OVERT AND 
SUBCLINICAL HYPOTHYROIDISM IN GROUP 1. 
 
 
Maternal outcome 
Overt 
hypothyroidism 
(n=49) 
Subclinical 
Hypothyroidism 
(n=19)  
 
p. value 
Hypertensive 
disorders 
 
3 (6.1%) 
 
3 (15.8%) 
 
0.338 
 
Anaemia 
 
13 (26.5%) 
 
5 (26.3%) 
 
0.986 
 
Preterm labour 
 
 
3 (6.1%) 
 
 
3 (15.8%) 
 
 
0.338 
 
GDM 
 
20 (40.8%) 
 
3 (15.8%) 
 
0.050 
 
LSCS 
 
16 (32.7%) 
 
9 (47.4%) 
 
0.259 
 
Neonatal outcome 
 
 
  
 
Low birth weight 
 
5 (10.2%) 
 
4 (21.1%) 
 
0.253 
 
NICU admission 
 
9 (18.4%) 
 
5 (26.3%) 
 
0.512 
Cord TSH 
>25(mIu/L) 
 
1 (2.0%) 
 
 
2 (10.5%) 
 
0.187 
 
85 
 
 
 
On doing subgroup analysis of women in  group1, ( overt versus subclinical 
hypothyroidism ) there were no statistically significant differences for either  adverse 
maternal or neonatal outcomes between the types of hypothyroidism.(Table 4).  
Total 4  neonates had  cord TSH >25 m IU/L . Out of these , one baby was born to 
mother who was newly diagnosed to have hypothyroidism during pregnancy. 
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DISCUSSION 
 
Thyroid dysfunction is the most common endocrine disorder in pregnancy as per 
ACOG practice Bulletin 2001 (55). This prospective cohort study helped us to study 
the maternal and perinatal outcomes in women with thyroid dysfunction. 
There have been several studies, evaluating maternal and neonatal outcomes in 
women with hypothyroidism.(7,13,15,20) 
 
Few studies have compared the outcomes between hypothyroid and euthyroid women 
(28,56) Others have compared outcomes between pregnant women with overt and 
subclinical hypothyroidism (7,9,15). Few have compared outcomes between women 
with subclinical hypothyroidism and euthyroid.(49). Some of these studies are 
retrospective in nature(9) whereas others are prospective in nature(7,56). Few had 
both retrospective and prospective components (28)  
, 
Ours is a prospective cohort study which compared outcomes of pregnant women with 
and without hypothyroidism. We recruited   women with known hypothyroidism and 
those diagnosed for the very first time during pregnancy in Group1 and compared 
their outcomes with euthyroid women (Group2). Other studies which compared 
hypothyroid and euthyroid women, recruited hypothyroid women diagnosed for first 
time during pregnancy (7,56)  
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In Group1, 68 women had known thyroid dysfunction prior to pregnancy and 
59(46.4%) were diagnosed for the first time during pregnancy. Out of these, 72 % 
were overt and the rest were subclinical(Fig1). There were no overt cases amongst 
those diagnosed for the first time. 
 
Amongst those in whom hypothyroidism was diagnosed for the first time during 
pregnancy, the median age of diagnosis. 
was 12 weeks. Others have also reported similar findings (57)  
Most common reason for ordering TFTs in pregnancy was history of subfertility 
(47.5%) followed by presence of symptoms (25.4%). 
  
Twelve cases were picked up incidentally during routine antenatal bloods. (Fig 3). 
These blood tests were done elsewhere since we do not offer universal screening for 
thyroid dysfunction in pregnancy. 
 
Median Serum TSH levels in our cohort was 5.6 mIU/L with IQR being 4.5-7.6. 
(Figure 4) Median dose of levothyroxine(LT4) was 75 mcg in women with known 
hypothyroidism as compared to 50 mcg in those diagnosed during pregnancy. Women 
who were diagnosed to have subclinical hypothyroidism elsewhere   and were on 
thyroid medications, were continued on these drugs. Women who were diagnosed 
here during pregnancy, were started on thyroid medications as per Endocrine protocol. 
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 Nearly 34% women required an increase in the dosage of their medications. (Figure 
6) Abalovich et al studied the evolution of disease during the pregnancy, reported that 
nearly 70 % of their cohort required increased dose of medication during pregnancy. 
(15) 
The maternal characteristics were comparable in terms of age, parity   and previous 
obstetric history.(Table 1) Although there was statistically significant difference in the 
age of participants in both the groups (p value <0.001, Table 1), mean age being 
higher in group 1, this could be explained due to large sample size and may not be 
clinically significant.(58) 
 
History of miscarriages comparable in both hypothyroid and euthyroid groups. 
 
The difference in BMI in both groups was statistically significant (p value <0.001, 
Table 1). This can be explained by the fact that hypothyroidism is known to effect 
heavier women and vice versa (women are obese due to decreased metabolic rate as 
found in hypothyroidism). 
 
Significantly greater number of women in Group1 had hypertensive disorders of 
pregnancy. (15% vs 3.3 %, p value <0.001, Table 2). Nirmala et al found 3.8 times 
higher risk of developing gestational hypertension in women with hypothyroidism 
(28). 
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Others have also found increased incidence of gestational hypertension in women with 
hypothyroidism(7,21,56). Most of these studies have reported increased incidence 
with overt hypothyroidism over euthyroidism(21,56,59). This is in contrast to some 
studies where authors have found difference between euthyroid and both overt as well 
as subclinical hypothyroidism (7). 
 
We did not find statistically significant difference in maternal anaemia between the 
two groups (26% versus 17.1%, p value 0.08, Table2). This is consistent with findings 
in the study by Kishore et al.(7). This is contrast to findings reported by other authors, 
who have reported higher incidence of anaemia in overt hypothyroid pregnancies (56). 
  
Relationship between anaemia and thyroid dysfunction is not very clear. It has been 
hypothesized that iron deficiency might cause impairment of heme dependant thyroid 
peroxidase, which limits synthesis of thyroid hormones and can lead to 
hypothyroidism. This can be corrected by correcting the maternal anaemia (60). 
 
The incidence of preterm birth in both the groups were similar (5.5% vs 8.85, p value 
0.294, Table 2) This is in contrast to studies done by other researchers, who found an 
increased incidence of preterm birth and low birth weight secondary to prematurity. 
(7,59) Some have found this increased incidence even with subclinical 
hypothyroidism (7,49) 
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In a systematic review done by Sheehan et al (61), there was a small but highly 
statistically significant increase in risk of preterm labour in both hypothyroidism and 
hyperthyroidism. The major limitation of this review, however, was the studies 
included in it did not differentiate between spontaneous and iatrogenic preterm births 
 
The possible biological explanation for this is not very clear. It has been proposed that 
myometrium possesses thyroid hormone receptor, the presence of TSH and 
thyrotropin releasing hormone receptors have been demonstrated in the primate uterus 
(62).   TSH is also known to bind to HCG receptors which are present in the 
myometrium (63). 
 
Our study did not find increased risk of gestational diabetes in women with 
hypothyroidism (p value 0.102, Table 2). Karakosta et al found four-fold increase in 
incidence of gestational diabetes in women with elevated TSH and presence of thyroid 
antibodies (64). 
 
The LSCS rate in both the groups were similar (35.4% vs 31.7%, p value 0.533, Table 
2). This is in contrast to findings in other studies.(7,21,28,65). These studies have 
found foetal distress as the cause for increased LSCS rate in hypothyroid group 
(21,21,56).  
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Others have reported increased incidence of abruption with untreated hypothyroidism.  
(7,49)  We did not encounter abruptio placentae in either group 
. 
We did not have any cases of miscarriage in either group. This is in contrast to 
findings reported by others.(20,28,56). Abalovich et al found that overt as well as 
subclinical hypothyroidism was associated with miscarriages if left untreated. 
Incidence of miscarriage decreased if thyroid replacement was adequate (15). 
 
Overall, the incidence of maternal complications in our study was low in comparison 
to others  (7,21,28,56) This could be explained by the fact that majority of the 
pregnant women in Group1 were subclinical hypothyroid (19% among previously 
known cases and 100% in newly diagnosed cases)  
. 
 Casey et al. (49) comparing outcomes in subclinical hypothyroidism versus 
euthyroidism, found hypothyroid women were 3 times more likely to have placental 
abruption (relative risk 3.0, 95% CI 1.1-8.2). Preterm birth was almost two-fold higher 
in women with subclinical hypothyroidism. 
 
Our low incidence of complications could be explained by optimal treatment and strict 
follow up of hypothyroidism in pregnancy.  34% women in group1 required increased 
dosage of levothyroxine and none required reduction in the dosage of medications. 
This has been substantiated by Abalovich et al who stated that evolution of 
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pregnancies conceived under hypothyroidism did not depend upon severity of disease 
but adequacy of therapy.(15) 
We did not notice any increased adverse maternal outcome while comparing overt 
versus subclinical hypothyroidism. (Table 4). Sahu et al, comparing overt versus 
subclinical hypothyroidism found that incidence of gestational hypertension, 
gestational diabetes, foetal growth restriction. intrauterine demise and neonatal 
complications   were significantly higher in the overt group (65) 
 
Among the neonatal outcomes, we did not find significant difference in the incidence 
of preterm birth, delivery <37 weeks, and low birth weight babies (birth weight <2.5 
kgs) between both the groups (p values 0.890 and 0.656, Table 4) Leung et al had 
found increased incidence of low birth weight babies secondary to premature delivery 
or gestational hypertension in both overt and subclinical hypothyroidism(49). 
Others have found increased incidence of low birth weight in untreated 
hypothyroidism (56) 
 
Although we reported higher incidence of hypertensive disorders in Group1 in 
comparison to Group2, this did not reflect in our neonatal outcomes, as the incidence 
of low birth weight and foetal growth restriction were comparable in the two groups (p 
value 0.656 and 0.776, Table 3). This is in contrast to findings by others (7,56,65). 
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Our findings can be explained by the fact that most women in group 1 had mild to 
moderate gestational hypertension. The incidence of severe gestational hypertension 
and pre-eclampsia were similar in both groups (4.7% versus 2.3 %, p value) 
 
Significantly more number of babies from Group1 required NICU admission (20.4% 
versus 9.7%, p value 0.018). This is in spite of the fact that incidence of low birth 
weight and foetal growth restriction was similar in both groups. (Table 3) 
 
On analysing, reasons for NICU admission in babies born to hypothyroid mothers, we 
found that majority (27%) of babies went to NICU for causes, such as presence of 
congenital anomaly, and patent ductus arteriosus which are unlikely related to 
maternal hypothyroid status. (Fig 11) Other causes for neonatal admission like 
sepsis/hypoglycaemia and neonatal jaundice were comparable in both groups. (Fig 11) 
One neonate had severe asphyxia and died after 6 hours of life. The parturient had 
ruptured uterus following induction of labour and underwent emergency laparotomy 
for the same. (Fig 11) 
 
Rajalakshmi et al found increased incidence of NICU admissions in babies born to 
mothers with untreated hypothyroidism. They had also found increased occurrence of 
foetal growth restriction and low birth weight in these babies (56) 
We found 4 cases (3.1%) of neonatal hypothyroidism in Group 1 and none in Group 2 
(p value 0.122, Table 3). Similar findings have been reported by others.(56) 
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CONCLUSIONS 
 
In conclusion, we found that evolution of disease during pregnancy does not depend   
upon the degree of hypothyroidism, whether overt or subclinical, but on the therapy 
received.  
 
Timely initiation of therapy and close treatment monitoring to titrate the dose of 
individual thyroid medications is of paramount importance in prevention of obstetric 
and neonatal complications. 
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LIMITATIONS 
 
The limitations of our study are, we did not test for thyroid antibodies due to financial 
constraints. Thyroid peroxidase antibodies have been identified as risk factors for 
obstetric complications such as miscarriage, preterm birth, gestational diabetes (34,64) 
 
We did not do long term follow up of the neonates born to hypothyroid mothers. A 
number of observational studies have found that children born to mothers with 
untreated hypothyroidism during pregnancy have lower IQ scores when compared 
with those born to euthyroid women  (3,66). 
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STUDY PROFORMA 
 
Name:                                     Age:                            H. NO: 
 
Address:                                 BMI (prepregancy):                          Mobile: 
 
Booked / Unbooked : 
Obstetric Score: 
 
Previous Obstetric History: 
 
Any comorbid Medical conditions: 
 
A. known case of Hypothyroidism:                               Y/N 
 
If Yes, Overt/subclinical:                                                  
106 
 
 
     Duration of disease: 
 
     On Thyroxine:          Y/N                                Dose:          Mcg          
 
     Compliance: Y/N 
 
     TFTs at diagnosis: 
      S.TSH: 
     S. T4 Levels: 
     S.FTc: 
      
 B.Diagnosed during pregnancy:                                    Y/N 
 
GA at diagnosis:              weeks 
 
TFTs at diagnosis: 
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S.TSH : 
S.T4 Levels: 
S.FTc: 
 
Reason for ordering TFTs in pregnancy:  
1) Symptomatic 
2) Increased BMI (>40 Kg/m2) 
3) Recurrent 1st Trimester miscarriages 
4) Infertility 
5) Family  history of Thyroid disorder  
6) History of head or neck radiation 
7) Coming from area of Iodine deficiency 
8) Type 1 Diabetes 
Thyroxine started:          Y/N                                Dose:          Mcg 
 
Repeat TFTs: 
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C. Alteration in dose of medications:             Y/N 
 
Dosage at   1st Trimester 
 
                     2nd Trimester 
 
                     3rd Trimester 
 
D.   Maternal complications:             Y/N.   
 
If yes, specify:            
 
a)Miscarriages 
 
b)Gestational HTN/ Preeclampsia 
  
c)  Preterm labor   
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d) Anemia 
                                               
  e)Gestational DM 
 
f)Antepartum / Postpartum hemorrhage           
   
 
   g)Others           
 
Any intervention done for above complications:     Y/N 
Specify 
 
E. Labor and delivery  details. 
GA at delivery: 
 
Preterm Labor: 
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Mode of delivery:        NVD / Instrumental delivery/ LSCS   
 
If LSCS/ instrumental delivery,   indication: 
 
Postpartum Haemorrhage : Y/N                                
 
F. Neonatal Outcome  
 
    Gestational age 
    Gender: 
   APGAR score: 
 
Birth weight at delivery: 
 
Cord blood TSH levels: 
 
111 
 
G. Neonatal complications: 
 
  Fetal growth restriction: 
                                              
   Intrauterine demise: 
                                              
  Admission to Neonatal ICU : 
                                               
 Neonatal Jaundice 
                                             
  Neonatal Death with cause 
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Data Entry Sheet 
 
SLNO IDNO GROUP AGE age_r BMI bmi_r CHECKUP OBSTETRI PREOBST deleteCOMORBID HT DM BA HYPOTHY HYPOYES DURATION THYROXIN THYXODOS COMPLIAN STSH ST4 SFTC DIAGPREG GADIAG GA_diag_r
8 1 25 2 28.60 2 1 2 1 2 0 2 1 20.0 2
114 1 25 2 24.60 1 1 2 5 2 0 2 2 1 12.0 1
2 1 24 1 38.40 4 1 1 4 2 0 2 1 8.0 1
7 1 27 2 23.90 1 1 1 4 2 0 2 1 4.0 1
10 1 26 2 25.00 2 1 1 4 2 0 2 1 12.0 1
11 1 23 1 28.00 2 1 1 4 2 0 2 2 2 1 12.0 1
15 1 31 3 32.40 3 1 2 2 2 0 2 1 12.0 1
19 1 24 1 24.00 1 1 1 4 2 0 2 1 12.0 1
25 1 27 2 23.40 1 1 1 4 2 0 2 2 1 4.0 1
28 1 25 2 36.10 4 1 2 1 2 0 2 2 1 8.0 1
30 1 28 2 30.80 2 1 1 4 2 0 2 2 1 12.0 1
32 1 30 3 22.10 1 1 1 4 2 0 2 2 1 12.0 1
33 1 31 3 28.60 2 1 1 4 2 0 2 2 1 10.0 1
34 1 28 2 26.10 2 1 2 5 1 0 2 2 1 4.0 1
35 1 32 3 28.40 2 1 2 3 2 0 2 2 1 4.0 1
37 1 22 1 22.20 1 1 1 4 2 0 2 2 1 12.0 1
40 1 26 2 27.30 2 1 2 1 2 0 2 2 1 8.0 1
41 1 26 2 23.90 1 1 1 4 2 0 2 2 1 12.0 1
47 1 31 3 24.30 1 1 2 1 2 0 2 2 1 16.0 2
51 1 30 3 28.60 2 1 2 3 2 0 2 2 1 18.0 2
52 1 25 2 29.30 2 1 1 4 2 0 2 1 4.0 1
53 1 22 1 18.40 1 1 1 4 2 0 2 2 1 19.0 2
54 1 23 1 19.50 1 1 1 4 2 0 2 2 1 4.0 1
60 1 27 2 30.30 2 1 1 4 2 0 2 2 1 10.0 1
62 1 21 1 26.50 2 1 1 4 2 0 2 2 1 12.0 1
63 1 29 2 25.00 2 1 2 1 2 0 2 2 1 12.0 1
64 1 26 2 30.10 2 1 1 4 2 0 2 2 1 8.0 1
65 1 25 2 28.00 2 1 2 1 2 0 2 2 1 12.0 1
66 1 22 1 24.40 1 1 1 4 2 0 2 2 1 16.0 2
67 1 26 2 28.30 2 1 2 3 2 0 2 2 1 8.0 1
68 1 31 3 29.40 2 1 1 4 2 0 2 2 1 12.0 1
69 1 28 2 40.20 5 1 2 1 2 0 2 2 1 16.0 2
70 1 25 2 24.80 1 1 1 4 2 0 2 2 1 4.0 1
71 1 19 0 20.80 1 1 1 4 2 0 2 2 1 4.0 1
72 1 22 1 30.00 2 1 1 4 2 0 2 2 1 12.0 1
74 1 35 4 28.30 2 1 2 1 2 0 2 2 1 16.0 2
75 1 28 2 25.70 2 1 1 4 2 0 2 2 1 16.0 2
76 1 22 1 40.20 5 1 2 1 2 0 2 2 1 16.0 2
77 1 28 2 21.00 1 1 2 5 2 0 2 2 1 20.0 2
79 1 37 4 26.50 2 1 2 5 2 0 2 2 1 12.0 1
81 1 26 2 26.70 2 1 1 4 2 0 2 2 1 12.0 1
84 1 29 2 31.60 3 1 1 2 2 0 2 2 1 12.0 1
87 1 31 3 32.00 3 1 2 3 2 0 2 2 1 12.0 1
89 1 22 1 29.20 2 1 1 4 2 0 2 2 1 12.0 1
91 1 23 1 30.50 2 1 2 1 2 0 2 2 1 12.0 1
94 1 28 2 27.00 2 1 2 3 2 0 2 2 1 12.0 1
99 1 23 1 28.59 2 1 1 4 2 0 2 2 1 12.0 1
105 1 29 2 29.80 2 1 1 4 2 0 2 2 1 16.0 2
106 1 31 3 25.40 2 1 1 4 2 0 2 2 1 19.0 2
110 1 23 1 36.20 4 1 1 4 2 0 2 2 1 20.0 2
112 1 19 0 20.70 1 1 1 4 2 0 2 2 1 10.0 1
113 1 32 3 27.50 2 1 2 3 2 0 2 2 1 16.0 2
115 1 27 2 28.00 2 1 2 3 2 0 2 2 1 12.0 1
117 1 24 1 28.70 2 1 2 3 2 0 2 2 1 8.0 1
118 1 35 4 14.80 1 1 1 4 2 0 2 2 1 19.0 2
119 1 24 1 27.00 2 1 1 4 2 0 2 2 1 12.0 1
125 1 28 2 28.40 2 1 2 1 2 0 2 2 1 12.0 1
161 36 2 20 1 26.10 2 1 1 4 2 0 2 2 1 20.0 2
168 43 2 20 1 29.10 2 1 1 4 2 0 2 2 1 20.0 2
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ga_diag_r1 PREGSTSH PREGST4 PREGSFTC REASON SYMPTOM INCRESEB TRIMESTE INFERTIL THYROID HEADNECK IODINE DIABTYPE THYROXI1 THYROXDO REPSTSH REPST4 REPSFTC MEDICAT TRIMEST1 TRIMEST2 TRIMEST3 MATERNAL MISCARRI GASTAHTN GHTN
ga_diag_r2 PREGSTSH PREGST5 PREGSFTC REASON SYMPTOM INCRESEB TRIMESTE INFERTIL THYROID HEADNECK IODINE DIABTYPE THYROXI2 THYROXDO REPSTSH REPST5 REPSFTC MEDICAT TRIMEST1 TRIMEST2 TRIMEST3 MATERNAL MISCARRI GASTAHTN GHTN
ga_diag_r3 PREGSTSH PREGST6 PREGSFTC REASON SYMPTOM INCRESEB TRIMESTE INFERTIL THYROID HEADNECK IODINE DIABTYPE THYROXI3 THYROXDO REPSTSH REPST6 REPSFTC MEDICAT TRIMEST1 TRIMEST2 TRIMEST3 MATERNAL MISCARRI GASTAHTN GHTN
ga_diag_r4 PREGSTSH PREGST7 PREGSFTC REASON SYMPTOM INCRESEB TRIMESTE INFERTIL THYROID HEADNECK IODINE DIABTYPE THYROXI4 THYROXDO REPSTSH REPST7 REPSFTC MEDICAT TRIMEST1 TRIMEST2 TRIMEST3 MATERNAL MISCARRI GASTAHTN GHTN
ga_diag_r5 PREGSTSH PREGST8 PREGSFTC REASON SYMPTOM INCRESEB TRIMESTE INFERTIL THYROID HEADNECK IODINE DIABTYPE THYROXI5 THYROXDO REPSTSH REPST8 REPSFTC MEDICAT TRIMEST1 TRIMEST2 TRIMEST3 MATERNAL MISCARRI GASTAHTN GHTN
ga_diag_r6 PREGSTSH PREGST9 PREGSFTC REASON SYMPTOM INCRESEB TRIMESTE INFERTIL THYROID HEADNECK IODINE DIABTYPE THYROXI6 THYROXDO REPSTSH REPST9 REPSFTC MEDICAT TRIMEST1 TRIMEST2 TRIMEST3 MATERNAL MISCARRI GASTAHTN GHTN
ga_diag_r7 PREGSTSH PREGST10PREGSFTC REASON SYMPTOM INCRESEB TRIMESTE INFERTIL THYROID HEADNECK IODINE DIABTYPE THYROXI7 THYROXDO REPSTSH REPST10REPSFTC MEDICAT TRIMEST1 TRIMEST2 TRIMEST3 MATERNAL MISCARRI GASTAHTN GHTN
ga_diag_r8 PREGSTSH PREGST11PREGSFTC REASON SYMPTOM INCRESEB TRIMESTE INFERTIL THYROID HEADNECK IODINE DIABTYPE THYROXI8 THYROXDO REPSTSH REPST11REPSFTC MEDICAT TRIMEST1 TRIMEST2 TRIMEST3 MATERNAL MISCARRI GASTAHTN GHTN
ga_diag_r9 PREGSTSH PREGST12PREGSFTC REASON SYMPTOM INCRESEB TRIMESTE INFERTIL THYROID HEADNECK IODINE DIABTYPE THYROXI9 THYROXDO REPSTSH REPST12REPSFTC MEDICAT TRIMEST1 TRIMEST2 TRIMEST3 MATERNAL MISCARRI GASTAHTN GHTN
ga_diag_r10PREGSTSH PREGST13PREGSFTC REASON SYMPTOM INCRESEB TRIMESTE INFERTIL THYROID HEADNECK IODINE DIABTYPE THYROXI10THYROXDO REPSTSH REPST13REPSFTC MEDICAT TRIMEST1 TRIMEST2 TRIMEST3 MATERNAL MISCARRI GASTAHTN GHTN
ga_diag_r11PREGSTSH PREGST14PREGSFTC REASON SYMPTOM INCRESEB TRIMESTE INFERTIL THYROID HEADNECK IODINE DIABTYPE THYROXI11THYROXDO REPSTSH REPST14REPSFTC MEDICAT TRIMEST1 TRIMEST2 TRIMEST3 MATERNAL MISCARRI GASTAHTN GHTN
ga_diag_r12PREGSTSH PREGST15PREGSFTC REASON SYMPTOM INCRESEB TRIMESTE INFERTIL THYROID HEADNECK IODINE DIABTYPE THYROXI12THYROXDO REPSTSH REPST15REPSFTC MEDICAT TRIMEST1 TRIMEST2 TRIMEST3 MATERNAL MISCARRI GASTAHTN GHTN
ga_diag_r13PREGSTSH PREGST16PREGSFTC REASON SYMPTOM INCRESEB TRIMESTE INFERTIL THYROID HEADNECK IODINE DIABTYPE THYROXI13THYROXDO REPSTSH REPST16REPSFTC MEDICAT TRIMEST1 TRIMEST2 TRIMEST3 MATERNAL MISCARRI GASTAHTN GHTN
ga_diag_r14PREGSTSH PREGST17PREGSFTC REASON SYMPTOM INCRESEB TRIMESTE INFERTIL THYROID HEADNECK IODINE DIABTYPE THYROXI14THYROXDO REPSTSH REPST17REPSFTC MEDICAT TRIMEST1 TRIMEST2 TRIMEST3 MATERNAL MISCARRI GASTAHTN GHTN
ga_diag_r15PREGSTSH PREGST18PREGSFTC REASON SYMPTOM INCRESEB TRIMESTE INFERTIL THYROID HEADNECK IODINE DIABTYPE THYROXI15THYROXDO REPSTSH REPST18REPSFTC MEDICAT TRIMEST1 TRIMEST2 TRIMEST3 MATERNAL MISCARRI GASTAHTN GHTN
ga_diag_r16PREGSTSH PREGST19PREGSFTC REASON SYMPTOM INCRESEB TRIMESTE INFERTIL THYROID HEADNECK IODINE DIABTYPE THYROXI16THYROXDO REPSTSH REPST19REPSFTC MEDICAT TRIMEST1 TRIMEST2 TRIMEST3 MATERNAL MISCARRI GASTAHTN GHTN
ga_diag_r17PREGSTSH PREGST20PREGSFTC REASON SYMPTOM INCRESEB TRIMESTE INFERTIL THYROID HEADNECK IODINE DIABTYPE THYROXI17THYROXDO REPSTSH REPST20REPSFTC MEDICAT TRIMEST1 TRIMEST2 TRIMEST3 MATERNAL MISCARRI GASTAHTN GHTN
ga_diag_r18PREGSTSH PREGST21PREGSFTC REASON SYMPTOM INCRESEB TRIMESTE INFERTIL THYROID HEADNECK IODINE DIABTYPE THYROXI18THYROXDO REPSTSH REPST21REPSFTC MEDICAT TRIMEST1 TRIMEST2 TRIMEST3 MATERNAL MISCARRI GASTAHTN GHTN
ga_diag_r19PREGSTSH PREGST22PREGSFTC REASON SYMPTOM INCRESEB TRIMESTE INFERTIL THYROID HEADNECK IODINE DIABTYPE THYROXI19THYROXDO REPSTSH REPST22REPSFTC MEDICAT TRIMEST1 TRIMEST2 TRIMEST3 MATERNAL MISCARRI GASTAHTN GHTN
ga_diag_r20PREGSTSH PREGST23PREGSFTC REASON SYMPTOM INCRESEB TRIMESTE INFERTIL THYROID HEADNECK IODINE DIABTYPE THYROXI20THYROXDO REPSTSH REPST23REPSFTC MEDICAT TRIMEST1 TRIMEST2 TRIMEST3 MATERNAL MISCARRI GASTAHTN GHTN
ga_diag_r21PREGSTSH PREGST24PREGSFTC REASON SYMPTOM INCRESEB TRIMESTE INFERTIL THYROID HEADNECK IODINE DIABTYPE THYROXI21THYROXDO REPSTSH REPST24REPSFTC MEDICAT TRIMEST1 TRIMEST2 TRIMEST3 MATERNAL MISCARRI GASTAHTN GHTN
ga_diag_r22PREGSTSH PREGST25PREGSFTC REASON SYMPTOM INCRESEB TRIMESTE INFERTIL THYROID HEADNECK IODINE DIABTYPE THYROXI22THYROXDO REPSTSH REPST25REPSFTC MEDICAT TRIMEST1 TRIMEST2 TRIMEST3 MATERNAL MISCARRI GASTAHTN GHTN
ga_diag_r23PREGSTSH PREGST26PREGSFTC REASON SYMPTOM INCRESEB TRIMESTE INFERTIL THYROID HEADNECK IODINE DIABTYPE THYROXI23THYROXDO REPSTSH REPST26REPSFTC MEDICAT TRIMEST1 TRIMEST2 TRIMEST3 MATERNAL MISCARRI GASTAHTN GHTN
ga_diag_r24PREGSTSH PREGST27PREGSFTC REASON SYMPTOM INCRESEB TRIMESTE INFERTIL THYROID HEADNECK IODINE DIABTYPE THYROXI24THYROXDO REPSTSH REPST27REPSFTC MEDICAT TRIMEST1 TRIMEST2 TRIMEST3 MATERNAL MISCARRI GASTAHTN GHTN
ga_diag_r25PREGSTSH PREGST28PREGSFTC REASON SYMPTOM INCRESEB TRIMESTE INFERTIL THYROID HEADNECK IODINE DIABTYPE THYROXI25THYROXDO REPSTSH REPST28REPSFTC MEDICAT TRIMEST1 TRIMEST2 TRIMEST3 MATERNAL MISCARRI GASTAHTN GHTN
ga_diag_r26PREGSTSH PREGST29PREGSFTC REASON SYMPTOM INCRESEB TRIMESTE INFERTIL THYROID HEADNECK IODINE DIABTYPE THYROXI26THYROXDO REPSTSH REPST29REPSFTC MEDICAT TRIMEST1 TRIMEST2 TRIMEST3 MATERNAL MISCARRI GASTAHTN GHTN
ga_diag_r27PREGSTSH PREGST30PREGSFTC REASON SYMPTOM INCRESEB TRIMESTE INFERTIL THYROID HEADNECK IODINE DIABTYPE THYROXI27THYROXDO REPSTSH REPST30REPSFTC MEDICAT TRIMEST1 TRIMEST2 TRIMEST3 MATERNAL MISCARRI GASTAHTN GHTN
ga_diag_r28PREGSTSH PREGST31PREGSFTC REASON SYMPTOM INCRESEB TRIMESTE INFERTIL THYROID HEADNECK IODINE DIABTYPE THYROXI28THYROXDO REPSTSH REPST31REPSFTC MEDICAT TRIMEST1 TRIMEST2 TRIMEST3 MATERNAL MISCARRI GASTAHTN GHTN
ga_diag_r29PREGSTSH PREGST32PREGSFTC REASON SYMPTOM INCRESEB TRIMESTE INFERTIL THYROID HEADNECK IODINE DIABTYPE THYROXI29THYROXDO REPSTSH REPST32REPSFTC MEDICAT TRIMEST1 TRIMEST2 TRIMEST3 MATERNAL MISCARRI GASTAHTN GHTN
ga_diag_r30PREGSTSH PREGST33PREGSFTC REASON SYMPTOM INCRESEB TRIMESTE INFERTIL THYROID HEADNECK IODINE DIABTYPE THYROXI30THYROXDO REPSTSH REPST33REPSFTC MEDICAT TRIMEST1 TRIMEST2 TRIMEST3 MATERNAL MISCARRI GASTAHTN GHTN
ga_diag_r31PREGSTSH PREGST34PREGSFTC REASON SYMPTOM INCRESEB TRIMESTE INFERTIL THYROID HEADNECK IODINE DIABTYPE THYROXI31THYROXDO REPSTSH REPST34REPSFTC MEDICAT TRIMEST1 TRIMEST2 TRIMEST3 MATERNAL MISCARRI GASTAHTN GHTN
ga_diag_r32PREGSTSH PREGST35PREGSFTC REASON SYMPTOM INCRESEB TRIMESTE INFERTIL THYROID HEADNECK IODINE DIABTYPE THYROXI32THYROXDO REPSTSH REPST35REPSFTC MEDICAT TRIMEST1 TRIMEST2 TRIMEST3 MATERNAL MISCARRI GASTAHTN GHTN
ga_diag_r33PREGSTSH PREGST36PREGSFTC REASON SYMPTOM INCRESEB TRIMESTE INFERTIL THYROID HEADNECK IODINE DIABTYPE THYROXI33THYROXDO REPSTSH REPST36REPSFTC MEDICAT TRIMEST1 TRIMEST2 TRIMEST3 MATERNAL MISCARRI GASTAHTN GHTN
ga_diag_r34PREGSTSH PREGST37PREGSFTC REASON SYMPTOM INCRESEB TRIMESTE INFERTIL THYROID HEADNECK IODINE DIABTYPE THYROXI34THYROXDO REPSTSH REPST37REPSFTC MEDICAT TRIMEST1 TRIMEST2 TRIMEST3 MATERNAL MISCARRI GASTAHTN GHTN
ga_diag_r35PREGSTSH PREGST38PREGSFTC REASON SYMPTOM INCRESEB TRIMESTE INFERTIL THYROID HEADNECK IODINE DIABTYPE THYROXI35THYROXDO REPSTSH REPST38REPSFTC MEDICAT TRIMEST1 TRIMEST2 TRIMEST3 MATERNAL MISCARRI GASTAHTN GHTN
ga_diag_r36PREGSTSH PREGST39PREGSFTC REASON SYMPTOM INCRESEB TRIMESTE INFERTIL THYROID HEADNECK IODINE DIABTYPE THYROXI36THYROXDO REPSTSH REPST39REPSFTC MEDICAT TRIMEST1 TRIMEST2 TRIMEST3 MATERNAL MISCARRI GASTAHTN GHTN
ga_diag_r37PREGSTSH PREGST40PREGSFTC REASON SYMPTOM INCRESEB TRIMESTE INFERTIL THYROID HEADNECK IODINE DIABTYPE THYROXI37THYROXDO REPSTSH REPST40REPSFTC MEDICAT TRIMEST1 TRIMEST2 TRIMEST3 MATERNAL MISCARRI GASTAHTN GHTN
ga_diag_r38PREGSTSH PREGST41PREGSFTC REASON SYMPTOM INCRESEB TRIMESTE INFERTIL THYROID HEADNECK IODINE DIABTYPE THYROXI38THYROXDO REPSTSH REPST41REPSFTC MEDICAT TRIMEST1 TRIMEST2 TRIMEST3 MATERNAL MISCARRI GASTAHTN GHTN
ga_diag_r39PREGSTSH PREGST42PREGSFTC REASON SYMPTOM INCRESEB TRIMESTE INFERTIL THYROID HEADNECK IODINE DIABTYPE THYROXI39THYROXDO REPSTSH REPST42REPSFTC MEDICAT TRIMEST1 TRIMEST2 TRIMEST3 MATERNAL MISCARRI GASTAHTN GHTN
ga_diag_r40PREGSTSH PREGST43PREGSFTC REASON SYMPTOM INCRESEB TRIMESTE INFERTIL THYROID HEADNECK IODINE DIABTYPE THYROXI40THYROXDO REPSTSH REPST43REPSFTC MEDICAT TRIMEST1 TRIMEST2 TRIMEST3 MATERNAL MISCARRI GASTAHTN GHTN
ga_diag_r41PREGSTSH PREGST44PREGSFTC REASON SYMPTOM INCRESEB TRIMESTE INFERTIL THYROID HEADNECK IODINE DIABTYPE THYROXI41THYROXDO REPSTSH REPST44REPSFTC MEDICAT TRIMEST1 TRIMEST2 TRIMEST3 MATERNAL MISCARRI GASTAHTN GHTN
ga_diag_r42PREGSTSH PREGST45PREGSFTC REASON SYMPTOM INCRESEB TRIMESTE INFERTIL THYROID HEADNECK IODINE DIABTYPE THYROXI42THYROXDO REPSTSH REPST45REPSFTC MEDICAT TRIMEST1 TRIMEST2 TRIMEST3 MATERNAL MISCARRI GASTAHTN GHTN
ga_diag_r43PREGSTSH PREGST46PREGSFTC REASON SYMPTOM INCRESEB TRIMESTE INFERTIL THYROID HEADNECK IODINE DIABTYPE THYROXI43THYROXDO REPSTSH REPST46REPSFTC MEDICAT TRIMEST1 TRIMEST2 TRIMEST3 MATERNAL MISCARRI GASTAHTN GHTN
ga_diag_r44PREGSTSH PREGST47PREGSFTC REASON SYMPTOM INCRESEB TRIMESTE INFERTIL THYROID HEADNECK IODINE DIABTYPE THYROXI44THYROXDO REPSTSH REPST47REPSFTC MEDICAT TRIMEST1 TRIMEST2 TRIMEST3 MATERNAL MISCARRI GASTAHTN GHTN
ga_diag_r45PREGSTSH PREGST48PREGSFTC REASON SYMPTOM INCRESEB TRIMESTE INFERTIL THYROID HEADNECK IODINE DIABTYPE THYROXI45THYROXDO REPSTSH REPST48REPSFTC MEDICAT TRIMEST1 TRIMEST2 TRIMEST3 MATERNAL MISCARRI GASTAHTN GHTN
ga_diag_r46PREGSTSH PREGST49PREGSFTC REASON SYMPTOM INCRESEB TRIMESTE INFERTIL THYROID HEADNECK IODINE DIABTYPE THYROXI46THYROXDO REPSTSH REPST49REPSFTC MEDICAT TRIMEST1 TRIMEST2 TRIMEST3 MATERNAL MISCARRI GASTAHTN GHTN
ga_diag_r47PREGSTSH PREGST50PREGSFTC REASON SYMPTOM INCRESEB TRIMESTE INFERTIL THYROID HEADNECK IODINE DIABTYPE THYROXI47THYROXDO REPSTSH REPST50REPSFTC MEDICAT TRIMEST1 TRIMEST2 TRIMEST3 MATERNAL MISCARRI GASTAHTN GHTN
ga_diag_r48PREGSTSH PREGST51PREGSFTC REASON SYMPTOM INCRESEB TRIMESTE INFERTIL THYROID HEADNECK IODINE DIABTYPE THYROXI48THYROXDO REPSTSH REPST51REPSFTC MEDICAT TRIMEST1 TRIMEST2 TRIMEST3 MATERNAL MISCARRI GASTAHTN GHTN
ga_diag_r49PREGSTSH PREGST52PREGSFTC REASON SYMPTOM INCRESEB TRIMESTE INFERTIL THYROID HEADNECK IODINE DIABTYPE THYROXI49THYROXDO REPSTSH REPST52REPSFTC MEDICAT TRIMEST1 TRIMEST2 TRIMEST3 MATERNAL MISCARRI GASTAHTN GHTN
ga_diag_r50PREGSTSH PREGST53PREGSFTC REASON SYMPTOM INCRESEB TRIMESTE INFERTIL THYROID HEADNECK IODINE DIABTYPE THYROXI50THYROXDO REPSTSH REPST53REPSFTC MEDICAT TRIMEST1 TRIMEST2 TRIMEST3 MATERNAL MISCARRI GASTAHTN GHTN
ga_diag_r51PREGSTSH PREGST54PREGSFTC REASON SYMPTOM INCRESEB TRIMESTE INFERTIL THYROID HEADNECK IODINE DIABTYPE THYROXI51THYROXDO REPSTSH REPST54REPSFTC MEDICAT TRIMEST1 TRIMEST2 TRIMEST3 MATERNAL MISCARRI GASTAHTN GHTN
ga_diag_r52PREGSTSH PREGST55PREGSFTC REASON SYMPTOM INCRESEB TRIMESTE INFERTIL THYROID HEADNECK IODINE DIABTYPE THYROXI52THYROXDO REPSTSH REPST55REPSFTC MEDICAT TRIMEST1 TRIMEST2 TRIMEST3 MATERNAL MISCARRI GASTAHTN GHTN
ga_diag_r53PREGSTSH PREGST56PREGSFTC REASON SYMPTOM INCRESEB TRIMESTE INFERTIL THYROID HEADNECK IODINE DIABTYPE THYROXI53THYROXDO REPSTSH REPST56REPSFTC MEDICAT TRIMEST1 TRIMEST2 TRIMEST3 MATERNAL MISCARRI GASTAHTN GHTN
ga_diag_r54PREGSTSH PREGST57PREGSFTC REASON SYMPTOM INCRESEB TRIMESTE INFERTIL THYROID HEADNECK IODINE DIABTYPE THYROXI54THYROXDO REPSTSH REPST57REPSFTC MEDICAT TRIMEST1 TRIMEST2 TRIMEST3 MATERNAL MISCARRI GASTAHTN GHTN
ga_diag_r55PREGSTSH PREGST58PREGSFTC REASON SYMPTOM INCRESEB TRIMESTE INFERTIL THYROID HEADNECK IODINE DIABTYPE THYROXI55THYROXDO REPSTSH REPST58REPSFTC MEDICAT TRIMEST1 TRIMEST2 TRIMEST3 MATERNAL MISCARRI GASTAHTN GHTN
ga_diag_r56PREGSTSH PREGST59PREGSFTC REASON SYMPTOM INCRESEB TRIMESTE INFERTIL THYROID HEADNECK IODINE DIABTYPE THYROXI56THYROXDO REPSTSH REPST59REPSFTC MEDICAT TRIMEST1 TRIMEST2 TRIMEST3 MATERNAL MISCARRI GASTAHTN GHTN
ga_diag_r57PREGSTSH PREGST60PREGSFTC REASON SYMPTOM INCRESEB TRIMESTE INFERTIL THYROID HEADNECK IODINE DIABTYPE THYROXI57THYROXDO REPSTSH REPST60REPSFTC MEDICAT TRIMEST1 TRIMEST2 TRIMEST3 MATERNAL MISCARRI GASTAHTN GHTN
ga_diag_r58PREGSTSH PREGST61PREGSFTC REASON SYMPTOM INCRESEB TRIMESTE INFERTIL THYROID HEADNECK IODINE DIABTYPE THYROXI58THYROXDO REPSTSH REPST61REPSFTC MEDICAT TRIMEST1 TRIMEST2 TRIMEST3 MATERNAL MISCARRI GASTAHTN GHTN
ga_diag_r59PREGSTSH PREGST62PREGSFTC REASON SYMPTOM INCRESEB TRIMESTE INFERTIL THYROID HEADNECK IODINE DIABTYPE THYROXI59THYROXDO REPSTSH REPST62REPSFTC MEDICAT TRIMEST1 TRIMEST2 TRIMEST3 MATERNAL MISCARRI GASTAHTN GHTN
ga_diag_r60PREGSTSH PREGST63PREGSFTC REASON SYMPTOM INCRESEB TRIMESTE INFERTIL THYROID HEADNECK IODINE DIABTYPE THYROXI60THYROXDO REPSTSH REPST63REPSFTC MEDICAT TRIMEST1 TRIMEST2 TRIMEST3 MATERNAL MISCARRI GASTAHTN GHTN
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PE PRELABOR ANEMIA GESTADM ANTEPART OTHERS INTERVEN SPECIFY GADELIVE PREELABO DELIMODE LSCS LSCSINST POSTPART GESTAGE GA BABYGEND APGARSCO APGAR2 BIRTHWT bw t CORDBLOO cord_tsh NEONAT FETALGRO INTRAUTE
2 2 2 1 2  1 MNT 37.1 2 3 1 NRFS 2 37.1 2 2 9 10 2.540 2 7.25 2 1 1 2
2 2 2 2 2  2  39.1 2 1 2  2 39.1 2 1 9 10 2.460 1 18.82 2 1 1 2
2 2 2 2 2  1 BP MONITORING 39.4 2 1 2  2 39.4 2 1 9 10 3.310 2 13.52 2 1 2 2
2 2 2 1 2  1 MNT 39.3 2 2 2 NRFS 2 39.3 2 1 9 10 2.670 2 17.74 2 2 2 2
2 2 2 2 2  2  39.4 2 2 2 NRFS 2 39.4 2 2 9 10 2.650 2 6.72 2 2 2 2
2 2 2 2 2  2  40.3 2 2 2 CAT 2 NRFS 2 40.3 2 2 9 10 3.000 2 8.07 2 2 2 2
2 2 2 1 2  1 MNT 38.6 2 3 1 PREVIOUS LSCS 2 38.6 2 1 9 10 3.420 2 4.26 2 2 2 2
1 1 2 2 2  1 ANTIHYPERTENSIVE DRUGS, MGSO4 35.4 1 3 1 NRFS 2 35.4 1 1 9 9 1.120 1 16.23 2 1 1 2
2 2 2 2 2  2  40.3 2 3 1 NRFS 2 40.3 2 2 9 9 3.460 2 4.37 2 2 2 2
2 2 2 2 2  1 ANTIHYPERTENSIVE DRUGS 38.2 2 1 2  2 38.2 2 1 9 10 3.120 2 17.50 2 2 2 2
2 2 2 2 2  2  39.1 2 2 2 NRFS 2 39.1 2 1 9 10 3.160 2 4.02 2 2 2 2
2 2 2 1 2  1 MNT 39.1 2 1 2  2 39.1 2 2 9 10 3.070 2 5.36 2 1 2 2
2 2 2 1 2  1 MNT 38.4 2 2 2 NRFS 2 38.4 2 2 9 10 2.540 2 4.51 2 1 1 2
2 2 2 2 2  2  38.4 2 1 2  2 38.4 2 1 9 10 3.320 2 6.17 2 2 2 2
1 2 2 2 2  1 BP MONITORING 36.6 1 3 1 PREVIOUS LSCS, WITH BREECH 2 36.6 1 1 9 10 2.860 2 5.79 2 2 2 2
2 2 1 2 2  1 ORAL IRON 39.6 2 2 2 CAT 2 NRFS 2 39.6 2 1 9 10 2.000 1 5.94 2 1 1 2
2 2 1 2 2  1 ORAL IRON 38.3 2 1 2  2 38.3 2 2 9 10 2.800 2 5.79 2 1 2 2
2 2 1 1 2  1 MNT, ORAL IRON 38.4 2 3 1 NRFS, THINMSAF 2 38.4 2 1 9 10 2.540 2 4.90 2 1 2 2
2 2 1 2 2  1 ORAL IRON 39.0 2 1 2  2 39.0 2 1 9 10 2.700 2 6.11 2 2 2 2
2 2 2 2 2  2  39.3 2 1 2  2 39.3 2 1 9 10 2.960 2 5.43 2 2 2 2
2 2 1 2 2  1 BP MONITORING, ORAL IRON 38.5 2 2 2 NRFS 2 38.5 2 2 9 10 2.800 2 24.69 2 1 2 2
2 2 2 2 2  2  38.0 2 2 2 NRFS 2 38.0 2 2 9 10 2.030 1 4.27 2 1 1 2
2 2 1 2 2  1 ORAL IRON 39.2 2 1 2  2 39.2 2 2 9 10 2.800 2 9.63 2 2 2 2
2 2 2 2 2  2  38.6 2 1 2  2 38.6 2 1 9 10 2.830 2 4.83 2 2 2 2
2 2 2 2 2  2  38.5 2 1 2  2 38.5 2 2 9 10 3.330 2 5.05 2 2 2 2
2 2 1 2 2  1 ORAL IRON 38.1 2 1 2  2 38.1 2 2 9 10 2.680 2 10.10 2 2 2 2
2 2 2 2 2  2  38.4 2 3 1 CAT 2 NRFS 2 38.4 2 2 9 10 2.300 1 7.72 2 1 1 2
2 2 2 2 2  2  39.1 2 3 1 FAILED INDUCTION 2 39.1 2 2 9 9 3.220 2 15.23 2 2 2 2
1 2 2 2 2  1 MGSO4 40.1 2 3 1 ARREST OF DESCENT 2 40.1 2 2 9 9 3.600 2 6.22 2 2 2 2
2 2 2 1 2  1 BP MONITORING, OHA + INSULINE 38.5 2 3 1 PREVIOUS LSCS 2 38.5 2 2 9 9 3.420 2 5.52 2 2 2 2
2 2 2 2 2  2  39.3 2 2 2 CAT 2 NRFS 2 39.3 2 2 9 10 2.790 2 4.18 2 2 2 2
2 2 2 2 2  2  39.4 2 1 2  2 39.4 2 2 9 10 2.900 2 17.86 2 2 2 2
2 2 2 1 2  1 MNT 39.4 2 1 2  2 39.4 2 1 9 9 3.680 2 7.00 2 2 2 2
2 2 2 2 2  2  37.2 2 1 2  2 37.2 2 2 9 10 6.690 2 2.11 2 1 1 2
2 2 2 2 2  1 BP MONITORING 38.2 2 2 2 PROLONG 2ND STAGE 2 38.2 2 1 9 10 3.780 2 5.57 2 2 2 2
2 1 2 1 2  1 OHA + MNT 36.4 1 1 2  2 36.4 1 2 9 10 2.360 1 6.85 2 2 2 2
2 2 2 2 2  2  38.6 2 1 2  2 38.6 2 2 9 10 2.980 2 10.71 2 2 2 2
1 2 2 2 2  1 ANTIHYPERTENSIVE DRUGS 36.3 1 2 2 NRFS 2 36.3 1 1 9 10 2.800 2 29.62 1 2 2 2
2 2 1 2 2  1 ORAL IRON 38.0 2 3 1 PREVIOUS LSCS NOT WILLING FOR VBAC 2 38.0 2 2 9 10 3.000 2 3.30 2 2 2 2
2 2 1 2 2  1 ANEMIA RX WITH ORAL IRON, GHTN ON BP MONITORING 39.1 2 3 1  2 39.1 2 1 9 10 3.120 2 2.64 2 2 2 2
2 2 2 1 2  1 BP MONITORING 39.0 2 1 2  2 39.0 2 2 9 10 3.160 2 7.30 2 2 2 2
2 2 1 2 2  1 ORAL IRON 38.2 2 3 1 PROTRACTED DILATATION 2 38.2 2 2 9 10 2.460 1 11.23 2 1 1 2
2 2 2 2 2  2  39.5 2 3 1 PREVIOUS LSCS 2 39.5 2 1 9 9 3.680 2 8.12 2 2 2 2
2 2 2 2 2  2  39.5 2 3 1 CAT 2 NRFS 2 39.5 2 2 9 10 3.360 2 6.83 2 2 2 2
2 2 2 2 2  2  38.4 2 1 2  2 38.4 2 1 9 10 3.140 2 10.44 2 2 2 2
2 2 2 1 2  1 MNT 38.4 2 3 1 DOUBTFUL SCAR INTEGRITY 2 38.4 2 1 9 9 3.140 2 4.98 2 2 2 2
2 2 1 2 2  1 BP MONITORING, ORAL IRON 39.0 2 2 2 NRFS 2 39.0 2 2 9 10 2.800 2 24.69 2 1 2 2
2 2 1 2 2  1 ORAL IRON 37.1 2 2 2 NRFS 2 37.1 2 2 9 10 2.270 1 13.23 2 1 1 2
2 2 2 2 2  2  38.3 2 1 2  2 38.3 2 1 9 10 2.770 2 13.18 2 2 2 2
1 2 1 2 2  1 ORAL IRON, MGSO4 DELIVERY 38.0 2 3 1 SPE WITH DETERIORATION MATERNAL CONDITION 2 38.0 2 1 9 10 2.600 2 4.14 2 1 2 2
2 2 2 2 2  2  39.4 2 1 2  2 39.4 2 1 9 10 3.550 2 3.54 2 2 2 2
2 2 2 1 2  1 OHA 39.0 2 1 2  1 39.0 2 2 9 10 3.100 2 9.25 2 2 2 2
2 2 1 2 2  1 ORAL IRON 38.3 2 2 2 NRFS 2 38.3 2 1 7 8 3.250 2 10.34 2 2 2 2
2 2 2 2 2  2  40.2 2 1 2  2 40.2 2 2 9 10 2.850 2 7.12 2 2 2 2
2 1 2 2 2  1 ANTIHYPERTENSIVE DRUGS 33.4 1 3 1 SEVEN PRE ECLAMPSIA 2 33.4 1 2 9 10 1.420 1 8.56 2 1 2 2
2 2 1 2 2  1 ORAL IRON 39.6 2 3 1 NRFS 2 39.6 2 1 9 9 2.560 2 14.13 2 1 2 2
2 2 2 2 2  2  40.3 2 2 2 NRFS 40.3 2 1 7 9 3.440 2 9.32 2 1 2 2
2 2 1 2 2  1 ORAL IRON 41.1 2 1 2  2 41.1 2 2 9 10 2.560 2 12.71 2 2 2 2
1 2 2 2 2  1 ANTIHYPERTENSIVE DRUGS 39.3 2 3 1 NRFS 2 39.3 2 1 9 10 2.800 2 8.42 2 2 2 2
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NEONATIC Preterm LBW Jaundice Asphyxia Renalpelvisdilataion Sepsis Hypogylcemia TTN PDA Microcephaly TSH NEONATJA NEONATDE DEATHYES filter_$
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
1 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
1 1 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 1 2 2 2 2 2 2 2 2  1
1 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
1 2 2 1 2 2 2 2 2 2 2 2 2 2  1
1 2 2 2 2 2 2 2 2 2 1 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
1 2 2 2 2 2 2 2 2 2 2 1 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 1 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
1 2 2 2 2 2 2 2 2 2 2 1 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
1 2 2 2 2 2 2 1 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
1 2 2 2 2 2 2 2 1 2 2 2 2 2  1
1 2 2 2 2 2 2 2 1 2 2 2 2 2  1
1 2 2 2 1 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
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16 1 28 2 30.80 2 1 1 4 1 0 1 2 2.00 1 50 1 7.500 10.2 1.15 2 0
18 1 25 2 26.60 2 1 1 4 1 0 1 2 1.06 1 50 1 9.600 2 0
39 1 30 3 28.20 2 1 1 4 1 0 1 2 10.00 1 25 1 8.500 7.2 1.01 2 0
44 1 32 3 30.80 2 1 2 3 1 0 1 2 1.00 1 50 1 6.150 2 0
58 1 24 1 25.00 2 1 1 4 1 0 1 2 1.06 1 25 1 5.600 2 0
59 1 26 2 28.20 2 1 2 3 1 0 1 2 1.06 1 50 1 8.000 8.3 1.12 2 0
61 1 30 3 24.50 1 1 2 1 1 0 1 2 1.06 1 75 1 9.390 2 0
82 1 33 3 30.20 2 1 1 4 1 0 1 2 2.00 1 50 1 8.283 8.5 1.15 2 0
104 1 28 2 25.60 2 1 2 3 1 0 1 2 3.00 1 50 1 8.230 8.0 1.10 2 0
108 1 29 2 23.00 1 1 2 1 1 0 1 2 1.06 1 50 1 2 0
122 1 41 5 32.00 3 1 1 4 1 0 1 2 1.06 1 50 1 9.000 7.5 1.15 2 0
124 1 25 2 22.30 1 1 1 4 0 1 2 2.00 1 50 1 9.360 10.2 1.23 2 0
1 1 27 2 33.30 3 1 1 4 1 0 1 1 13.00 1 200 2 0
3 1 22 1 31.60 3 1 1 4 1 0 1 1 1.06 1 50 1 2 0
4 1 30 3 27.50 2 1 1 4 1 0 1 1 7.00 1 150 1 2 0
5 1 31 3 23.00 1 1 2 3 1 0 1 1 0.08 1 100 16.520 2 0
6 1 21 1 35.30 3 1 1 4 1 0 1 1 1 50 1 11.360 1.2 2 0
9 1 25 2 36.20 4 1 2 3 1 0 1 1 1 75 1 74.933 8.9 0.67 2 0
12 1 29 2 28.00 2 1 1 4 1 0 1 1 2.06 1 125 1 2 0
13 1 23 1 21.40 1 1 2 5 1 0 1 1 1.00 1 100 1 12.000 2 0
17 1 35 4 30.50 2 1 1 4 1 0 1 1 4.00 1 125 1 2 0
20 1 28 2 21.20 1 1 2 1 1 0 1 1 1.06 1 50 1 11.000 2 0
21 1 23 1 25.50 2 1 2 5 1 0 1 1 1.00 1 75 1 10.000 2 0
22 1 29 2 23.30 1 1 1 4 1 0 1 1 10.00 1 100 1 2 0
23 1 29 2 32.50 3 1 1 4 1 0 1 1 12.00 1 75 1 15.200 12.3 1.33 2 0
26 1 33 3 27.50 2 2 2 5 1 0 1 1 3.00 1 50 1 10.010 2 0
27 1 27 2 25.00 2 1 2 3 1 0 1 1 2.00 1 100 1 12.500 2 0
29 1 22 1 32.50 3 1 1 4 1 0 1 1 12.00 1 100 1 20.600 2 0
31 1 29 2 33.50 3 1 1 4 1 0 1 1 2.00 1 75 1 40.507 3.2 0.60 2 0
38 1 30 3 31.20 3 1 2 3 1 0 1 1 2.00 1 200 160.000 2 0
43 1 28 2 19.90 1 1 1 4 1 0 1 1 3.00 1 75 1 12.000 2 0
45 1 29 2 34.20 3 1 2 3 1 0 1 1 5.00 1 50 1 10.520 2 0
46 1 28 2 30.20 2 2 2 2 1 0 1 1 3.00 1 100 1 19.127 2 0
48 1 30 3 28.30 2 1 2 5 1 0 1 1 6.00 1 150 1 23.400 2 0
49 1 34 3 30.20 2 1 2 3 1 0 1 1 6.00 1 100 20.500 2 0
55 1 32 3 26.70 2 1 2 5 1 0 1 1 5.00 1 75 1 9.500 10.5 1.02 2 0
56 1 26 2 27.30 2 1 1 4 1 0 1 1 3.00 1 100 1 23.000 1.8 0.28 2 0
57 1 28 2 32.40 3 1 2 3 1 0 1 1 2.00 1 75 1 10.520 2 0
73 1 33 3 27.00 2 1 2 5 1 0 1 1 2.00 1 100 1 14.640 10.6 1.23 2 0
78 1 32 3 28.60 2 1 2 3 1 0 1 1 6.00 1 100 1 22.300 2 0
80 1 28 2 28.10 2 1 1 4 1 0 1 1 7.00 1 125 1 20.000 2 0
85 1 27 2 29.50 2 1 1 4 1 0 1 1 5.00 1 75 1 2 0
86 1 29 2 28.20 2 1 2 5 1 0 1 1 4.00 1 100 1 11.200 2 0
88 1 29 2 38.40 4 1 2 3 1 0 1 1 5.00 1 50 1 2 0
90 1 28 2 24.70 1 1 2 3 1 0 1 1 14.00 1 50 1 2 0
92 1 28 2 32.40 3 1 1 4 1 0 1 1 11.00 1 75 14.423 12.2 1.18 2 0
93 1 24 1 24.70 1 1 2 1 1 0 1 1 2.00 1 50 1 2 0
95 1 31 3 29.10 2 1 1 4 1 0 1 1 3.00 1 150 1 2 0
96 1 25 2 28.50 2 1 1 4 1 0 1 1 2.00 1 50 1 11.400 2 0
97 1 23 1 23.80 1 1 1 4 1 0 1 1 1.06 1 100 1 27.000 2 0
98 1 36 4 32.40 3 1 1 4 1 0 1 1 6.00 1 150 1 20.400 2 0
100 1 27 2 23.90 1 1 2 5 1 0 1 1 6.00 1 50 1 11.887 12.5 0.92 2 0
101 1 32 3 27.50 2 1 1 4 1 0 1 1 5.00 1 25 1 115.000 2 0
102 1 20 1 30.00 2 1 2 5 1 0 1 1 4.00 1 100 1 2 0
103 1 34 3 26.00 2 1 2 5 1 0 1 1 7.00 1 50 1 100.000 2 0
107 1 27 2 26.00 2 1 1 4 1 0 1 1 2.00 1 100 1 12.500 10.9 1.23 2 0
109 1 27 2 25.00 2 1 2 3 1 0 1 1 3.00 1 150 1 92.999 1.9 0.49 2 0
111 1 20 1 30.70 2 1 1 4 1 0 1 1 1.00 1 75 2 0
116 1 22 1 29.50 2 1 2 3 1 0 1 1 10.00 1 200 217.000 7.2 0.54 2 0
120 1 32 3 34.20 3 1 2 3 1 0 1 1 3.00 1 100 1 23.200 2 0
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1.00 1 2 2 2 1 2 2 2 2 1.660 15.20 1.22 1 75 2 2 2 2
1.00 2 0 0 0 2 4.880 1 75 2 2 2 2
1.00 1 2 2 2 1 2 2 2 2 2 0.990 2 1 2 2 2
1.00 2 0 0 0 1 1.432 13.40 1.10 2 2 2 2 2
1.00 1 2 2 2 1 2 2 2 2 2 1.672 2 2 2 2 2
1.00 2 0 0 0 2 4.617 14.00 1.07 1 75 1 2 2 2
1.00 2 0 0 0 2 6.999 1 100 1 2 2 2
1.00 2 0 0 0 2 1.312 2 1 2 2 2
1.00 2 0 0 0 2 1.060 14.80 1.12 2 2 2 2 2
1.00 1 2 2 2 1 2 2 2 2 2 2.301 2 1 2 1 2
1.00 1 2 2 2 1 2 2 2 2 2 10.070 1 100 1 2 2 2
1.00 1 2 2 2 1 2 2 2 2 2 3.489 1 75 1 2 2 2
1.00 2 0 0 0 2.600 2 2 2 2 2
1.00 2 0 0 0 4.100 11.20 1.20 1 125 1 2 2 2
1.00 2 0 0 0 14.143 13.20 1.19 1 200 1 2 2 2
1.00 2 0 0 0 1.970 2 1 2 2 2
1.00 2 0 0 0 1 75 2.537 1 75 1 2 1 1
1.00 2 0 0 0 6.876 1 100 2 2 2 2
1.00 1 2 2 2 1 2 2 2 2 0.827 2 2 2 2 2
1.00 2 0 0 0 2.300 1 50 2 2 2 2
1.00 2 0 0 0 1.833 16.60 1.16 1 150 2 2 2 2
1.00 2 0 0 0 1.900 1 75 2 2 2 2
1.00 2 0 0 0 2 2 2 2 2 2
1.00 2 0 0 0 2 29.000 2 1 2 2 2
1.00 2 0 0 0 2 1.814 2 1 2 2 2
1.00 2 0 0 0 2 1.955 12.50 1.22 2 1 2 2 2
1.00 2 0 0 0 2 1.940 2 2 2 2 2
1.00 2 0 0 0 2 0.353 1 150 2 2 2 2
1.00 2 0 0 0 2 0.675 1 100 2 2 2 2
1.00 2 0 0 0 2 2.076 14.70 1.23 2 2 2 2 2
1.00 2 0 0 0 2 2.668 8.40 1.08 1 100 1 2 2 2
1.00 2 0 0 0 2 2 2 2 2 2
1.00 2 0 0 0 2 0.093 15.40 1.41 1 150 1 2 2 2
1.00 2 0 0 0 2 2.930 2 1 2 2 2
1.00 2 0 0 0 2 0.045 2 1 2 2 2
1.00 0.560 14.2 1.04 2 0 0 0 2 0.560 14.20 1.04 2 2 2 2 2
1.00 2 0 0 0 2 4.414 1 150 1 2 2 2
1.00 2 0 0 0 2 1.051 15.70 1.04 1 150 2 2 2 2
1.00 2 0 0 0 2 4.882 6.40 0.97 1 125 2 2 2 1
1.00 2 0 0 0 2 3.282 2 2 2 2 2
1.00 2 0 0 0 2 0.848 1 150 2 2 2 2
1.00 2 0 0 0 2 2.652 1 100 1 2 1 1
1.00 2 0 0 0 2 2.900 2 1 2 2 2
1.00 2 0 0 0 2 1.801 2 1 2 2 2
1.00 2 0 0 0 2 2.300 10.90 0.97 2 1 2 2 2
1.00 2 0 0 0 2 5.834 1 100 1 2 2 2
1.00 2 0 0 0 2 2.500 2 1 2 2 2
1.00 2 0 0 0 2 1.400 1.18 2 1 2 1 1
1.00 2 0 0 0 2 8.600 1 100 1 2 2 2
1.00 2 0 0 0 2 3.491 9.00 1.28 1 175 1 2 2 2
1.00 2 0 0 0 2 1.684 16.20 1.29 2 2 2 2 2
1.00 2 0 0 0 2 3.217 1 100 1 2 2 2
1.00 2 0 0 0 2 1 100 1 2 2 2
1.00 2 0 0 0 2 13.90 1.79 2 2 2 2 2
1.00 2 0 0 0 2 4.600 8.60 1 75 1 2 2 2
1.00 2 0 0 0 2 2.587 14.90 1.05 2 2 2 2 2
1.00 2 0 0 0 2 0.011 2 1 2 2 2
1.00 2 0 0 0 2 0.983 2 1 2 2 2
1.00 2 0 0 0 2 3.600 1 250 1 2 2 2
1.00 2 0 0 0 2 0.562 1 100 2 2 2 2
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2 2 2 2 2  2  38.0 2 2 2 NRFS 2 38.0 2 2 9 10 2.890 2 33.09 1 2 2 2
2 2 2 2 2  1 BIWEEKLY MONITORING, IOL 39.5 2 3 1 NRFS 2 39.5 2 2 9 9 2.300 1 5.68 2 1 1 2
2 2 1 1 2  1 ORAL IRON 38.1 2 3 1 CAPERATORRY FOR RUPTURE UTERUS 1 38.1 2 1 0 1 3.150 2 5.30 2 1 2 2
2 2 2 2 2  2  39.2 2 1 2  2 39.2 2 1 9 10 2.890 2 6.99 2 2 2 2
2 2 2 2 2  2  39.2 2 3 1 NRFS 2 39.2 2 1 9 10 2.980 2 6.88 2 1 2 2
2 2 2 1 2  1 MNT 37.3 2 1 2  2 37.3 2 1 9 10 3.340 2 6.10 2 1 2 2
2 2 2 1 2  1 OHA 38.0 2 3 1 FAILED INDUCTION 2 38.0 2 2 9 10 2.600 2 18.82 2 2 2 2
2 2 1 2 2  1 ORAL IRON 39.0 2 3 1 NRFS 2 39.0 2 2 9 10 3.000 2 8.40 2 2 2 2
2 2 2 2 2  2  40.2 1 2  2 40.2 2 2 9 10 3.260 2 5.12 2 2 2 2
1 2 2 2 2  1 ANTIHYPERTENSIVE DRUGS, MGSO4 40.0 2 2 2 PROLONG 2ND STAGE 2 40.0 2 1 9 10 2.780 2 8.32 2 2 2 2
2 1 2 2 2  2  36.3 1 3 1 IUGR WITH ABNORMAL DOPPLER 2 36.3 1 2 9 9 1.700 1 6.89 2 1 1 2
2 1 2 2 2  2  36.6 1 1 2  2 36.6 1 1 9 10 2.130 1 5.94 2 1 1 2
2 2 2 2 2  2  40.1 2 2 2 CAT 2 NRFS 2 40.1 2 1 9 10 2.700 2 10.70 2 2 2 2
2 2 2 1 2  1 OHA 38.6 2 2 2 CAT 2 NRFS 2 38.6 2 1 9 9 3.100 2 7.93 2 2 2 2
2 2 2 1 2  1 OHA 38.5 2 1 2  2 38.5 2 2 9 10 2.700 2 6.95 2 1 2 2
2 2 2 1 2  1 MNT 39.0 2 1 2  2 39.0 2 1 9 10 3.490 2 7.19 2 1 2 2
2 2 1 1 2  1 MNT, BP MONITORING, ORAL 38.4 2 3 1 BREECH WITH ECV 2 38.4 2 1 9 10 4.160 2 4.11 2 2 2 2
2 2 2 2 2  2  39.2 2 3 1 PREVIOUS LSCS WITH FAILED INDUCTION 2 39.2 2 1 9 9 2.920 2 3.74 2 2 2 2
2 2 2 2 2  2  40.3 2 3 1 UNFAVOURABLE CERVIX IVF PREGNANCY 2 40.3 2 1 9 10 2.920 2 5.93 2 2 2 2
2 2 2 2 2  2  40.1 2 3 1 NRFS 2 40.2 2 1 9 10 3.480 2 5.54 2 2 2 2
2 2 2 2 2  2  39.1 2 3 1 CAT 2 NRFS 2 39.1 2 2 9 10 3.100 2 6.59 2 2 2 2
2 2 2 2 2  2  40.0 2 3 1 ARREST OF DILATATION 2 40.1 2 2 9 10 3.060 2 4.23 2 2 2 2
2 2 2 2 2  2  40.2 2 1 2  2 40.2 2 1 9 10 3.410 2 20.65 2 2 2 2
2 2 2 1 2  1 MNT 38.4 2 2 2 CAT 2 NRFS 2 38.2 2 2 9 10 2.900 2 1.67 2 2 2 2
2 2 1 1 2  1 MNT, ORAL IRON 38.4 2 2 2 NRFS 2 38.4 2 2 9 10 2.960 2 1.67 2 2 2 2
2 1 1 1 2  1 MNT, ORAL IRON 35.3 2 1 2  2 35.3 1 2 9 10 2.840 2 10.77 2 2 2 2
2 2 2 2 2  2  39.2 2 1 2  2 39.2 2 1 9 10 3.520 2 4.10 2 2 2 2
2 2 2 2 2  2  39.2 2 3 1 CAT 2 NRFS 2 39.2 2 1 9 10 3.260 2 17.62 2 2 2 2
2 2 2 2 2  2  38.6 1 2  38.6 2 2 9 10 2.340 1 18.85 2 1 1 2
2 2 2 2 2  2  38.1 2 1 2  2 38.1 2 1 9 10 2.830 2 4.35 2 2 2 2
2 1 1 2 2 IUGR - 1.4KG AFI 1 ORAL IRON 34.3 1 3 1 FAILED INDUCTION 2 34.3 1 2 9 10 1.540 1 9.42 2 1 1 1
2 2 2 2 2  2  37.5 2 1 2  2 37.5 2 1 9 9 2.440 1 15.23 2 1 1 2
2 2 2 1 2  1 OHA 39.2 2 3 1 CORD PROLAPSE 2 39.2 2 1 9 10 3.280 2 4.33 2 2 2 2
2 2 1 2 2  1 ORAL IRON 40.1 2 1 2  2 40.1 2 2 9 10 3.500 2 4.46 2 2 2 2
2 2 2 1 2  1 OHA + INSULINE 38.6 2 1 2  2 38.6 2 1 9 10 2.740 2 13.97 2 1 2 2
2 2 2 2 2  2  39.0 2 1 2  2 39.0 2 2 9 10 2.950 2 7.76 2 2 2 2
2 2 1 1 2  1 MNT, ORAL IRON 40.0 2 2 2 CAT 2 NRFS 2 40.0 2 1 9 9 3.050 2 17.45 2 1 2 2
2 2 2 2 2  1  40.1 2 1 2  2 40.1 2 1 9 10 3.720 2 9.55 2 2 2 2
2 2 2 2 2  2  38.3 2 1 2  2 38.3 2 2 9 10 2.930 2 8.62 2 2 2 2
2 2 2 2 2  2  39.0 2 1 2  2 39.0 2 2 9 10 3.280 2 6.25 2 2 2 2
2 2 2 2 2  2  39.2 2 1 2  2 39.2 2 1 9 10 3.712 2 7.12 2 2 2 2
2 2 2 1 2  1 MNT, BP MONITORING 37.2 2 3 1 BREECH WITH GHTN 2 37.2 2 1 9 10 3.060 2 7.15 2 2 2 2
2 2 1 2 2  1 ORAL IRON 40.1 2 1 2  2 40.1 2 2 9 10 3.500 2 4.46 2 2 2 2
2 2 2 1 2  1 OHA 39.3 2 1 2  2 39.3 2 1 9 10 2.950 2 67.58 1 1 2 2
2 2 2 1 2  1 MNT 40.5 2 1 2  2 40.5 2 2 9 10 3.440 2 8.81 2 2 2 2
2 2 1 2 2  1 ORAL IRON 38.3 2 3 1 ARREST OF DESCENT 2 38.3 2 2 9 10 3.960 2 3.31 2 1 2 2
2 2 2 1 2  2  37.4 1 2  37.3 2 2 9 10 2.630 2 21.65 2 2 2 2
2 2 1 1 2  1 GDM ON OHA, BP MONITORING, ORAL IRON 39.5 2 2 2 NRFS 2 39.5 2 2 9 10 2.900 2 14.08 2 2 2 2
2 2 2 1 2  1 MNT 39.5 2 3 1 CAT 2 NRFS 2 39.5 2 2 5 9 3.540 2 6.17 2 2 2 2
2 2 2 1 2  1 MNT 38.6 2 1 2  2 38.6 2 1 9 10 2.840 2 5.15 2 2 2 2
2 2 2 2 2  2  38.6 2 3 1 NRFS 2 38.6 2 1 9 9 2.820 2 5.68 2 2 2 2
2 2 1 2 2  1 ORAL IRON 39.4 2 2 2 PROLONG 2ND STAGE 2 39.4 2 2 9 9 3.240 2 6.67 2 2 2 2
2 2 1 2 2  1 ORAL IRON 39.0 2 3 1 CAT 2 NRFS 2 39.0 2 2 9 9 2.960 2 3.69 2 2 2 2
2 2 2 2 2  2  39.0 2 1 2  2 39.0 2 1 9 10 2.800 2 7.65 2 1 2 2
2 2 2 1 2  1 OHA 37.0 2 1 2  2 37.0 2 1 9 10 2.800 2 7.67 2 2 2 2
2 2 2 2 2  2  39.3 2 2 2 NRFS 2 39.3 2 2 9 10 2.820 2 22.22 2 2 2 2
2 2 1 2 2  1 ORAL IRON 37.4 2 3 1 PLACENTA PREVIA 2 37.4 2 2 9 10 2.840 2 3.09 2 2 2 2
2 2 2 1 2  1 OHA 33.6 1 3 1 FAILED INDUCTION FOR PPROM 2 33.6 1 1 9 10 2.400 1 8.57 2 1 2 2
2 2 1 1 2  1 MNT, ORAL IRON 38.4 2 1 2  2 38.4 2 2 9 10 2.470 1 4.65 2 2 2 2
2 2 2 2 2  2  39.5 2 1 2  2 39.5 2 2 9 10 3.160 2 8.32 2 2 2 2
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2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
1 2 2 2 1 2 2 2 2 2 2 2 2 1  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
1 2 2 2 2 1 2 2 2 2 2 2 2 2  1
1 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
1 1 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 1 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
1 2 2 2 2 1 2 2 2 2 2 2 2 2  1
1 2 2 2 2 2 2 1 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
1 1 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
1 2 2 1 2 2 2 2 2 2 2 2 1 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
1 2 2 1 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
1 2 2 2 2 2 2 2 2 2 2 1 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
1 2 2 2 2 2 1 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
1 2 2 2 2 2 1 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
1 2 2 2 2 2 2 1 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
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121 1 38 4 27.20 2 1 2 5 1 0 1 1 8.00 1 50 1 12.700 2 0
14 1 25 2 30.10 2 1 1 4 1 0 1 2 2.00 1 100 1 2 0
24 1 24 1 30.70 2 1 2 5 1 0 1 2 2.00 1 50 1 7.016 2 0
36 1 33 3 28.00 2 1 2 3 1 0 1 2 1.06 1 50 1 8.367 6.7 0.90 2 0
42 1 26 2 23.60 1 1 2 1 1 0 1 2 3.00 1 25 1 2 0
83 1 26 2 34.10 3 1 1 4 1 0 1 2 6.00 1 75 1 2 0
50 1 32 3 29.20 2 1 2 5 1 0 2 2 8.00 1 75 1 2 0
123 1 29 2 36.50 4 1 2 1 2 0 2 2 1 25 5.200 2 0
126 1 2 26 2 26.50 2 1 2 5 2 0 2 2 2 0
127 2 2 19 0 40.50 5 1 2 1 1 0 2 2 2 0
128 3 2 21 1 28.20 2 1 1 4 2 0 2 2 2 0
129 4 2 28 2 24.50 1 1 1 4 2 0 2 2 2 0
130 5 2 20 1 23.60 1 1 1 4 2 0 2 2 2 0
131 6 2 18 0 20.30 1 1 1 4 2 0 2 2 2 0
132 7 2 30 3 17.20 1 1 2 3 2 0 2 2 2 0
133 8 2 23 1 21.50 1 1 1 4 2 0 2 2 2 0
134 9 2 24 1 20.90 1 1 2 1 2 0 2 2 2 0
135 10 2 34 3 22.90 1 1 2 3 2 0 2 2 2 0
136 11 2 24 1 22.50 1 1 1 4 2 0 2 2 2 0
137 12 2 30 3 30.60 2 1 1 4 2 0 2 2 2 0
138 13 2 36 4 30.00 2 1 1 4 2 0 2 2 2 0
139 14 2 29 2 22.50 1 1 2 3 2 0 2 2 2 0
140 15 2 31 3 25.40 2 1 2 3 2 0 2 2 2 0
141 16 2 24 1 20.50 1 1 1 4 2 0 2 2 2 0
142 17 2 20 1 25.00 2 1 2 2 2 0 2 2 2 0
143 18 2 21 1 24.00 1 1 1 4 2 0 2 2 2 0
144 19 2 26 2 24.50 1 1 1 4 2 0 2 2 2 0
145 20 2 31 3 23.40 1 1 1 4 2 0 2 2 2 0
146 21 2 24 1 23.00 1 1 2 3 2 0 2 2 2 0
147 22 2 25 2 34.00 3 1 1 4 2 0 2 2 2 0
148 23 2 25 2 28.20 2 1 1 4 2 0 2 2 2 0
149 24 2 24 1 20.10 1 1 1 4 2 0 2 2 2 0
150 25 2 26 2 20.50 1 1 2 3 2 0 2 2 2 0
151 26 2 24 1 27.20 2 1 1 4 2 0 2 2 2 0
152 27 2 33 3 29.50 2 1 2 3 2 0 2 2 2 0
153 28 2 28 2 24.20 1 1 2 3 2 1 2 2 2 0
154 29 2 28 2 25.60 2 1 2 3 2 1 2 2 2 0
155 30 2 20 1 24.00 1 1 1 4 2 0 2 2 2 0
156 31 2 26 2 24.50 1 1 1 4 2 0 2 2 2 0
157 32 2 27 2 28.20 2 1 2 1 2 0 2 2 2 0
158 33 2 20 1 26.10 2 1 1 4 2 0 2 2 2 0
159 34 2 26 2 22.90 1 1 1 4 2 0 2 2 2 0
160 35 2 22 1 30.80 2 1 2 3 2 0 2 2 2 0
162 37 2 22 1 23.00 1 1 2 3 2 0 2 2 2 0
163 38 2 30 3 30.70 2 1 2 5 2 0 2 2 2 0
164 39 2 20 1 16.40 1 1 1 4 2 0 2 2 2 0
165 40 2 18 0 22.40 1 1 1 4 2 0 2 2 2 0
166 41 2 18 0 22.40 1 1 1 4 2 0 2 2 2 0
167 42 2 22 1 24.50 1 1 1 4 2 0 2 2 2 0
169 44 2 29 2 28.00 2 1 1 4 2 0 2 2 2 0
170 45 2 25 2 28.00 2 1 1 4 2 0 2 2 2 0
171 46 2 26 2 28.00 2 1 2 5 2 0 2 2 2 0
172 47 2 23 1 23.40 1 1 1 4 2 0 2 2 2 0
173 48 2 24 1 29.10 2 1 1 4 2 0 2 2 2 0
174 49 2 31 3 37.00 4 1 2 4 2 0 2 2 2 0
175 50 2 26 2 24.30 1 1 2 3 2 0 2 2 2 0
176 51 2 21 1 27.70 2 1 1 4 2 0 2 2 2 0
177 52 2 30 3 27.90 2 1 2 1 2 0 2 2 2 0
178 53 2 33 3 18.60 1 1 2 3 2 0 2 2 2 0
179 54 2 17 0 19.30 1 1 1 4 2 0 2 2 2 0
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1.00 2 0 0 0 2 2.300 2 2 2 2 2
1.00 2 0 0 0 1.298 15.70 1.05 2 1 2 1 1
1.00 1 2 1 2 2 2 2 2 2 2 5.369 1 75 2 2 2 2
1.00 2 0 0 0 2 2.221 12.70 1.03 1 75 2 2 2 2
1.00 2 0 0 0 2 1.762 12.10 0.91 1 50 1 2 2 2
1.00 2 0 0 0 2 2 2 2 2 2
1.00 2 0 0 0 2 0.560 14.20 1.04 2 2 2 2 2
1.00 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2
2 0 0 0 2 1.030 2 1 2 2 2
2 0 0 0 2 2.350 2 2 2 2 2
2 0 0 0 2 2.300 2 1 2 2 2
2 0 0 0 2 1.023 2 1 2 2 2
2 0 0 0 2 2.350 2 2 2 2 2
2 0 0 0 2 0.684 2 1 2 2 2
2 0 0 0 2 1.026 2 2 2 2 2
2 0 0 0 2 1.608 2 2 2 2 2
2 0 0 0 2 2.189 2 2 2 2 2
2 0 0 0 2 3.874 2 2 2 2 2
1 2 2 2 1 2 2 2 2 2 1.893 2 2 2 2 2
2 0 0 0 2 2.500 2 1 2 2 2
2 0 0 0 2 1.551 2 1 2 2 2
2 0 0 0 2 2.530 2 1 2 2 2
2 0 0 0 2 2.759 2 2 2 2 2
1 2 2 2 1 2 2 2 2 2 2.859 2 2 2 2 2
2 0 0 0 2 2.030 2 2 2 2 2
2 0 0 0 2 2.350 2 2 2 2 2
2 0 0 0 2 1.360 2 2 2 2 2
2 0 0 0 2 2.350 2 1 2 2 2
2 0 0 0 2 2.530 2 2 2 2 2
2 0 0 0 2 2.221 2 2 2 2 2
2 0 0 0 2 2.300 2 2 2 2 2
2 0 0 0 2 1.449 2 1 2 2 2
2 0 0 0 2 2.000 2 2 2 2 2
2 0 0 0 2 3.190 2 2 2 2 2
2 0 0 0 2 1.065 2 2 2 2 2
2 0 0 0 2 2.530 2 2 2 2 2
2 0 0 0 2 2.350 2 2 2 2 2
2 0 0 0 2 2.033 2 2 2 2 2
2 0 0 0 2 2.665 2 1 2 2 2
2 0 0 0 2 0.631 2 1 2 2 2
2 0 0 0 2 2.121 2 2 2 2 2
1 2 2 2 1 2 2 2 2 2 1.025 2 1 2 2 2
2 0 0 0 2 2.305 2 1 2 2 2
2 0 0 0 2 2.350 2 1 2 2 2
2 0 0 0 2 1.646 2 2 2 2 2
2 0 0 0 2 2.089 2 2 2 2 2
2 0 0 0 2 2.520 2 1 2 2 2
2 0 0 0 2 1.350 2 2 2 2 2
1 2 2 2 1 2 2 2 2 2 2.346 2 2 2 2 2
1 2 2 2 1 2 2 2 2 2 1.020 2 2 2 2 2
2 0 0 0 2 2.858 2 2 2 2 2
2 0 0 0 2 2.530 2 2 2 2 2
2 0 0 0 2 2.050 2 2 2 2 2
2 0 0 0 2 2.800 2 2 2 2 2
2 0 0 0 2 2.656 2 2 2 2 2
1 2 2 2 1 2 2 2 2 2 2.050 2 2 2 2 2
2 0 0 0 2 3.000 2 2 2 2 2
2 0 0 0 2 1.396 2 2 2 2 2
2 0 0 0 2 1.415 2 2 2 2 2
2 0 0 0 2 2.729 2 2 2 2 2
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2 2 2 2 2  2  37.0 2 1 2  2 37.0 2 2 9 10 2.910 2 7.54 2 2 2 2
2 2 1 2 2  1 BP MONITORING, ORAL IRON 39.3 2 3 1 CAT 3 NRFS 2 39.3 2 1 7 10 3.000 2 6.30 2 2 2 2
2 2 2 2 2  2  40.3 2 1 2  2 40.3 2 2 9 10 3.680 2 11.46 2 2 2 2
2 2 2 2 2  2  35.4 1 2  2 35.4 1 2 9 10 1.960 1 30.77 1 1 1 2
2 2 1 2 2  1 ORAL IRON 39.3 2 3 1 FLEXED BREECH 2 39.3 2 2 9 9 2.680 2 9.25 2 2 2 2
2 2 2 2 2  2  38.1 2 2 2 CAT 2 NRFS 2 38.1 2 2 9 10 2.900 2 12.44 2 2 2 2
2 2 2 2 2  2  37.0 2 1 2  2 37.0 2 2 9 10 2.950 2 7.76 2 2 2 2
2 2 2 1 2  1 MNT 29.0 1 3 1 BREECH WITH CHORIOAMNITIS 2 29.0 1 1 6 8 1.280 1 2.25 2 1 2 2
2 1 2 1 2  1 MNT 36.6 1 3 1 PREVIOUS LSCS 2 36.6 1 1 9 10 3.220 2 6.35 2 1 2 2
2 2 2 2 2  2  38.3 2 1 2  2 38.3 2 1 9 10 2.390 1 20.47 2 1 1 2
2 2 2 1 2  1 MNT 40.2 2 2 2 NRFS 2 40.2 2 2 9 10 2.960 2 8.52 2 2 2 2
2 2 2 1 2  1 OHA 38.1 2 3 1 PRIMI BREECH 2 38.1 2 1 9 10 3.100 2 2.82 2 1 2 2
2 2 2 2 2  2  38.4 2 1 2  2 38.4 2 2 9 10 2.350 1 11.45 2 1 1 2
2 1 2 2 2  2  33.3 1 3 1 FAILED INDUCTION 2 33.3 1 1 9 10 2.120 1 4.98 2 1 2 2
2 1 2 2 2  2  40.0 2 1 2 FAILED INDUCTION 2 40.0 2 2 9 10 3.220 2 5.88 2 2 2 2
2 2 2 2 2  2  38.2 2 2 2 NRFS 2 38.2 2 1 9 10 2.900 2 7.02 2 2 2 2
2 2 2 2 2  2  40.2 2 1 2  2 40.2 2 2 9 10 2.700 2 7.75 2 2 2 2
2 2 2 2 2  2  39.4 2 3 1 PREVIOUS LSCS 2 39.4 2 1 9 10 2.800 2 8.52 2 2 2 2
2 2 2 2 2  2  39.0 2 3 1 FAILED INDUCTION 2 39.0 2 1 9 10 2.960 2 2.63 2 2 2 2
2 2 2 1 2  1 MNT 39.6 2 2 2 NRFS 2 39.6 2 1 7 9 3.300 2 12.38 2 2 2 2
2 1 2 1 2  1 MNT 35.0 1 3 1 MAJOR DEGREE PLACENTA PREVIA 1 35.0 1 1 9 10 2.400 1 6.66 2 2 2 2
2 2 1 2 2  1 ORAL IRON 38.4 2 3 1 PREVIOUS LSCS 2 38.4 2 2 9 10 2.640 2 3.26 2 2 2 2
2 2 2 2 2  2  38.3 2 1 2  2 38.3 2 1 9 10 3.140 2 13.12 2 2 2 2
2 2 2 2 2  2  39.2 2 1 2  2 39.2 2 1 9 10 2.740 2 15.46 2 2 2 2
2 2 2 2 2  2  38.1 2 3 1 PREVIOUS LSCS 2 38.1 2 2 9 10 2.880 2 6.45 2 2 2 2
2 2 2 2 2  2  38.4 2 2 2 NRFS 2 38.4 2 2 9 10 2.550 2 7.70 2 1 2 2
2 2 2 2 2  2  39.1 2 3 1 FAILED INDUCTION 2 39.1 2 1 9 10 3.100 2 2.96 2 2 2 2
2 2 1 2 2  1 ORAL IRON 40.3 2 3 1 FAILED INDUCTION 2 40.3 2 1 9 10 2.940 2 5.58 2 2 2 2
2 2 2 2 2  2  39.5 2 3 1 PREVIOUS LSCS 2 39.5 2 2 9 9 3.640 2 4.36 2 2 2 2
2 2 2 2 2  2  38.3 2 1 2  2 38.3 2 1 9 10 3.030 2 10.03 2 2 2 2
2 2 2 2 2  2  38.1 2 2 2 NRFS 2 38.1 2 1 9 10 2.340 1 5.93 2 2 2 2
2 2 1 2 2  1 ORAL IRON 39.0 2 1 2  2 39.0 2 1 9 10 2.670 2 7.85 2 2 2 2
2 2 2 2 2  2  37.2 2 3 1 PREVIOUS LSCS 2 37.2 2 1 9 10 3.000 2 4.83 2 2 2 2
2 2 2 2 2  2  38.4 2 1 2  2 38.4 2 1 9 10 3.200 2 20.47 2 2 2 2
2 2 2 2 2  2  40.2 2 1 2  2 40.2 2 2 9 10 3.450 2 5.49 2 2 2 2
2 2 2 2 2  2  38.2 2 3 1 PREVIOUS LSCS 2 38.2 2 1 9 10 2.720 2 5.60 2 2 2 2
2 2 2 2 2  2  38.6 2 1 2  2 38.6 2 1 9 10 3.330 2 9.63 2 1 2 2
2 2 2 2 2  2  39.3 2 1 2  2 39.3 2 2 9 10 2.980 2 5.60 2 2 2 2
2 2 2 1 2  1 MNT 39.5 2 2 2 NRFS 2 39.5 2 2 9 10 2.960 2 5.56 2 2 2 2
2 2 2 1 2  1 MNT 40.1 2 3 1 NRFS 2 40.1 2 2 9 10 3.200 2 4.71 2 2 2 2
2 2 2 2 2  2  38.0 2 2 2 NRFS 2 38.0 2 2 9 9 2.770 2 16.55 2 2 2 2
2 2 2 1 2  1 OHA 39.2 2 1 2  2 39.2 2 2 9 10 2.710 2 5.75 2 2 2 2
2 2 1 2 2  1 ORAL IRON 40.2 2 1 2  2 40.2 2 1 9 10 3.290 2 7.12 2 1 1 2
2 2 1 2 2  1 ORAL IRON 39.5 2 1 2  2 39.5 2 2 9 10 3.380 2 5.49 2 1 2 2
2 2 2 2 2  2  40.6 2 3 1 NRFS 2 40.6 2 1 9 10 3.920 2 4.93 2 1 2 2
2 2 2 2 2  2  39.6 2 1 2  2 39.6 2 2 9 10 2.890 2 5.16 2 2 2 2
2 2 1 2 2  1 ORAL IRON 40.0 2 1 2  2 40.0 2 1 9 10 2.540 2 5.29 2 2 2 2
2 2 2 2 2  2  37.5 2 1 2  2 37.5 2 2 9 10 2.200 1 13.20 2 1 1 2
2 2 2 2 2  2  38.4 2 1 2  2 38.4 2 1 9 10 2.720 2 8.54 2 1 1 2
2 2 2 2 2  2  40.1 2 1 2  2 40.1 2 1 9 10 3.370 2 3.63 2 2 2 2
2 2 2 2 2  2  37.5 2 1 2  2 37.5 2 2 9 10 2.620 2 11.35 2 2 2 2
2 2 2 2 2  2  40.1 2 2 2 NRFS 2 40.1 2 2 9 10 2.770 2 12.59 2 2 2 2
2 2 2 2 2  2  37.3 2 2 2 NRFS 1 37.4 2 1 9 10 2.680 2 10.32 2 2 2 2
2 2 2 2 2  2  39.5 2 1 2  2 39.5 2 2 9 10 2.570 2 4.65 2 2 2 2
2 2 2 2 2  2  37.2 2 3 1 BREECH PRESENTATION 2 37.2 2 1 9 10 3.000 2 8.61 2 2 2 2
2 2 2 2 2  2  39.5 2 1 2  2 39.5 2 1 9 10 3.800 2 7.73 2 2 2 2
2 2 2 2 2  2  40.3 2 2 NRFS 2 40.3 2 1 7 9 4.020 2 13.68 2 2 2 2
2 2 2 2 2  2  39.2 2 3 1 NRFS 39.2 2 2 9 10 3.100 2 10.48 2 2 2 2
2 2 2 2 2  2  37.1 2 3 1 SCAR DEHISCENCE 2 37.1 2 1 9 10 3.120 2 4.74 2 2 2 2
2 2 2 2 2  2  39.2 2 1 2  2 39.2 2 2 9 10 2.800 2 4.87 2 2 2 2
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2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
1 2 1 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
2 2 2 2 2 2 2 2 2 2 2 2 2 2  1
1 1 2 2 2 2 2 2 2 2 2 2 2 2  1
1 2 2 2 2 2 2 1 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
1 2 2 2 2 2 2 1 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
1 1 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
1 2 2 1 2 2 2 2 2 2 2 2 1 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
1 2 2 1 2 2 2 2 2 2 2 2 1 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
1 2 2 2 2 2 2 1 2 2 2 2 2 2  0
1 2 2 2 2 2 2 2 1 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
124 
 
 
180 55 2 21 1 24.50 1 1 2 1 2 0 2 2 2 0
181 56 2 19 0 26.40 2 1 1 4 2 0 2 2 2 0
182 30 2 30 3 24.50 1 1 1 4 2 0 2 2 2 0
183 58 2 28 2 28.30 2 1 2 3 2 0 2 2 2 0
184 59 2 24 1 32.10 3 1 2 1 2 0 2 2 2 0
185 60 2 31 3 25.40 2 1 2 3 2 0 2 2 2 0
186 61 2 35 4 35.90 3 1 2 3 2 0 2 2 2 0
187 62 2 24 1 27.00 2 1 2 3 2 0 2 2 2 0
188 63 2 20 1 21.00 1 1 1 4 2 0 2 2 2 0
189 64 2 25 2 22.40 1 1 2 3 2 0 2 2 2 0
190 65 2 24 1 30.00 2 1 2 3 2 0 2 2 2 0
191 66 2 24 1 24.00 1 1 1 4 2 0 2 2 2 0
192 67 2 25 2 24.50 1 1 2 5 1 0 2 2 2 0
193 68 2 24 1 26.00 2 1 1 4 2 0 2 2 2 0
194 69 2 21 1 24.30 1 1 2 3 2 0 2 2 2 0
195 70 2 19 0 23.70 1 1 1 4 2 0 2 2 2 0
196 71 2 26 2 24.40 1 1 2 5 2 0 2 2 2 0
197 72 2 24 1 22.10 1 1 1 4 2 0 2 2 2 0
198 73 2 23 1 17.50 1 1 1 4 2 0 2 2 2 0
199 74 2 17 0 20.80 1 1 1 4 2 0 2 2 2 0
200 75 2 28 2 31.20 3 1 1 4 2 0 2 2 2 0
201 76 2 25 2 27.30 2 1 1 4 2 0 2 2 2 0
202 77 2 23 1 24.00 1 1 1 4 2 0 2 2 2 0
203 78 2 29 2 32.40 3 1 2 5 2 0 2 2 2 0
204 79 2 23 1 25.60 2 1 1 4 2 0 2 2 2 0
205 80 2 23 1 22.00 1 1 2 5 2 0 2 2 2 0
206 26 2 26 2 24.00 1 1 1 4 2 0 2 2 2 0
207 82 2 29 2 29.00 2 1 2 3 2 0 2 2 2 0
208 83 2 29 2 28.40 2 1 1 4 2 0 2 2 2 0
209 84 2 23 1 26.40 2 1 1 4 2 0 2 2 2 0
210 85 2 23 1 26.10 2 1 2 1 2 0 2 2 2 0
211 86 2 32 3 16.80 1 1 2 3 2 0 2 2 2 0
212 87 2 20 1 18.50 1 1 2 3 2 0 2 2 2 0
213 88 2 26 2 21.90 1 1 1 4 2 0 2 2 2 0
214 89 2 27 2 23.40 1 1 2 3 2 0 2 2 2 0
215 90 2 32 3 29.20 2 1 2 3 2 0 2 2 2 0
216 91 2 26 2 25.00 2 1 2 5 2 0 2 2 2 0
217 92 2 26 2 28.50 2 1 2 5 2 0 2 2 2 0
218 93 2 35 4 30.50 2 1 1 4 2 0 2 2 2 0
219 94 2 19 0 23.40 1 1 1 4 2 0 2 2 2 0
220 95 2 26 2 25.30 2 1 1 4 2 0 2 2 2 0
221 96 2 26 2 27.40 2 1 1 4 1 1 2 2 2 0
222 97 2 25 2 23.50 1 1 1 4 2 0 2 2 2 0
223 98 2 24 1 28.00 2 1 1 4 2 0 2 2 2 0
224 99 2 21 1 27.00 2 1 2 1 2 0 2 2 2 0
225 100 2 26 2 24.30 1 1 1 4 2 0 2 2 2 0
226 101 2 28 2 22.40 1 1 2 5 2 0 2 2 2 0
227 102 2 21 1 26.50 2 1 2 3 2 0 2 2 2 0
228 103 2 35 4 26.60 2 1 2 5 2 0 2 2 2 0
229 104 2 24 1 23.00 1 1 1 4 2 0 2 2 2 0
230 105 2 24 1 23.10 1 1 2 3 2 0 2 2 2 0
231 106 2 23 1 28.40 2 1 1 4 2 0 2 2 2 0
232 107 2 25 2 21.40 1 1 1 4 2 0 2 2 2 0
233 108 2 32 3 25.00 2 1 1 4 2 0 2 2 2 0
234 109 2 33 3 27.90 2 1 2 6 2 0 2 2 2 0
235 110 2 23 1 21.30 1 1 2 3 2 0 2 2 2 0
236 111 2 22 1 27.00 2 1 1 4 2 0 2 2 2 0
237 112 2 20 1 19.60 1 1 2 2 2 0 2 2 2 0
238 113 2 23 1 19.60 1 1 1 4 2 0 2 2 2 0
239 114 2 19 0 19.90 1 1 2 1 2 0 2 2 2 0
240 115 2 28 2 21.90 1 1 1 4 2 0 2 2 2 0
241 116 2 26 2 26.10 2 1 2 3 2 0 2 2 2 0
242 117 2 21 1 17.80 1 1 1 4 2 0 2 2 2 0
243 118 2 20 1 24.30 1 1 2 2 2 0 2 2 2 0
244 119 2 32 3 25.40 2 1 2 5 2 0 2 2 2 0
245 120 2 24 1 26.20 2 1 2 3 2 0 2 2 2 0
246 121 2 24 1 23.00 1 1 1 4 2 0 2 2 2 0
247 122 2 30 3 26.70 2 1 2 6 2 0 2 2 2 0
248 123 2 29 2 26.00 2 1 1 4 2 0 2 2 2 0
249 124 2 28 2 25.30 2 1 1 4 2 0 2 2 2 0
250 125 2 20 1 20.30 1 1 1 4 2 0 2 2 2 0
125 
 
 
2 0 0 0 2 1.330 2 1 2 2 2
2 0 0 0 2 2.360 2 2 2 2 2
2 0 0 0 2 2.580 2 1 2 2 2
2 0 0 0 2 1.230 2 1 2 2 2
1 2 2 2 1 2 2 2 2 2 2.502 2 1 2 2 2
2 0 0 0 2 2.405 2 2 2 2 2
1 2 2 2 1 2 2 2 2 2 2.224 2 1 2 1 1
2 0 0 0 2 2.312 2 2 2 2 2
2 0 0 0 2 0.954 2 1 2 2 2
2 0 0 0 1 2.778 2 1 2 2 2
2 0 0 0 2 2.520 2 2 2 2 2
2 0 0 0 2 1.050 2 1 2 2 2
2 0 0 0 2 0.891 2 1 2 2 2
2 0 0 0 2 0.748 2 2 2 2 2
2 0 0 0 2 2.718 2 2 2 2 2
2 0 0 0 2 1.865 2 1 2 2 2
2 0 0 0 2 0.799 2 2 2 2 2
2 0 0 0 2 1.382 2 1 2 2 2
2 0 0 0 2 1.415 2 2 2 2 2
2 0 0 0 2 2.500 2 1 2 2 2
1 2 2 2 1 2 2 2 2 1 2.107 2 2 2 2 2
2 0 0 0 2 2.520 2 2 2 2 2
2 0 0 0 2 1.250 2 2 2 2 2
2 0 0 0 2 1.375 2 1 2 2 2
2 0 0 0 2 1.855 2 2 2 2 2
2 0 0 0 2 0.791 2 2 2 2 2
2 0 0 0 2 1.530 2 1 2 2 2
1 2 1 2 2 2 2 2 2 2 1.498 2 2 2 2 2
1 2 2 2 1 2 2 2 2 2 2.591 2 1 2 2 2
2 0 0 0 2 1.324 2 2 2 2 2
1 2 2 2 1 2 2 2 2 2 1.735 2 2 2 2 2
2 0 0 0 2 1.258 2 2 2 2 2
2 0 0 0 2 2.676 2 2 2 2 2
2 0 0 0 2 2.560 2 1 2 1 2
2 0 0 0 2 1.450 2 2 2 2 2
2 0 0 0 2 2.030 2 1 2 2 2
2 0 0 0 2 1.230 2 1 2 2 2
2 0 0 0 2 2.520 2 1 2 1 2
2 0 0 0 2 2.350 2 2 2 2 2
2 0 0 0 2 2.530 2 2 2 2 2
2 0 0 0 2 2.030 2 2 2 2 2
2 0 0 0 2 2.530 2 2 2 2 2
2 0 0 0 2 1.330 2 2 2 2 2
2 0 0 0 2 2.080 2 1 2 2 2
2 0 0 0 2 1.733 2 2 2 2 2
2 0 0 0 2 1.703 2 1 2 2 2
2 0 0 0 2 1.166 2 2 2 2 2
2 0 0 0 2 1.179 2 2 2 2 2
2 0 0 0 2 3.220 2 1 2 2 2
2 0 0 0 2 1.025 2 1 2 2 2
2 0 0 0 2 1.702 2 2 2 2 2
2 0 0 0 2 1.095 2 2 2 2 2
2 0 0 0 2 2.984 2 1 2 2 2
1 2 2 2 1 2 2 2 2 2 2.800 2 1 2 2 2
1 2 2 2 1 2 2 2 2 2 1.562 2 1 2 2 2
2 0 0 0 2 1.873 2 1 2 2 2
2 0 0 0 2 0.990 2 1 2 2 2
2 0 0 0 2 2.703 2 2 2 2 2
1 2 2 2 1 2 2 2 2 2 0.940 2 2 2 2 2
2 0 0 0 2 3.300 2 1 2 2 2
1 2 2 2 1 2 2 2 2 2 2.300 2 1 2 1 1
2 0 0 0 2 0.806 2 1 2 2 2
2 0 0 0 2 1.932 2 1 2 2 2
2 0 0 0 2 0.769 2 2 2 2 2
2 0 0 0 2 1.350 2 2 2 2 2
2 0 0 0 2 1.450 2 2 2 2 2
1 2 2 2 2 1 2 2 2 2 1.625 2 2 2 2 2
2 0 0 0 2 2.030 2 2 2 2 2
2 0 0 0 2 1.851 2 1 2 2 2
2 0 0 0 2 1.110 2 2 2 2 2
2 0 0 0 2 1.066 2 1 2 2 2
126 
 
 
2 1 1 2 2  1 ORAL IRON 34.5 1 2 2 NRFS 2 34.5 1 1 9 10 2.520 2 5.19 2 1 2 2
2 2 2 2 2  2  40.2 2 1 2  2 40.2 2 1 9 10 3.300 2 4.26 2 2 2 2
2 2 2 1 2  1 MNT 39.1 2 3 1 PROTRACTED LABOUR 2 39.1 2 2 9 10 3.440 2 4.53 2 2 2 2
2 2 1 2 2  1 ORAL IRON 40.2 2 1 2  2 40.2 2 2 9 10 3.108 2 9.26 2 2 2 2
2 2 1 2 2  1 ORAL IRON 39.0 2 1 2  2 39.0 2 2 9 10 2.260 1 6.14 2 1 1 2
2 2 2 2 2  2  40.3 2 3 1 NRFS 2 40.3 2 2 9 10 3.060 2 4.22 2 2 2 2
2 1 1 2 2  1 MNT, ANTIHYPERTENSIVE DRUGS, MGSO4 28.6 1 3 1 SEVEN PRE ECLAMPSIA, BREECH + IUGR 2 28.6 1 2 9 9 0.901 1 8.18 2 1 1 2
2 2 2 2 2  2  39.0 2 1 2  2 39.0 2 1 9 10 2.940 2 5.25 2 2 2 2
2 2 1 1 2  1 MNT, ORAL IRON 40.0 2 3 1 NRFS 2 40.0 2 1 9 10 4.380 2 1.55 2 2 2 2
2 2 1 2 2  1 ORAL IRON 39.3 2 3 1 NRFS 2 39.3 2 2 9 10 2.800 2 1.21 2 2 2 2
2 2 2 2 2  2  39.6 2 1 2  39.6 2 1 9 10 3.520 2 9.24 2 2 2 2
2 2 2 1 2  1 MNT 38.1 2 1 2  2 38.1 2 1 9 10 3.000 2 20.55 2 2 2 2
2 2 1 2 2  1 ORAL IRON 37.3 2 2 2 CUT SHORT 2ND STAGE 2 37.3 2 2 9 10 2.160 1 3.62 2 1 1 2
2 2 2 2 2  2  37.2 2 2 2 NRFS 2 37.2 2 2 9 10 2.290 1 12.99 2 1 1 2
2 2 2 2 2  2  37.6 2 1 2  2 37.6 2 1 9 10 3.240 2 4.91 2 2 2 2
2 2 1 2 2  1 ORAL IRON 39.2 2 1 2  2 39.2 2 1 9 10 2.700 2 11.42 2 2 2 2
2 2 2 2 2  2  39.1 2 1 2  2 39.1 2 1 9 10 3.710 2 4.35 2 2 2 2
2 1 2 2 2  2  36.3 1 1 2  2 36.3 1 2 9 10 2.560 2 7.99 2 2 2 2
2 2 2 2 2  2  38.1 2 2 2 NRFS 2 38.1 2 1 9 10 2.899 2 4.86 2 1 1 2
2 1 2 2 2  2  32.5 1 3 1 NRFS 2 32.5 1 1 4 6 1.720 1 10.35 2 1 2 2
2 2 2 2 2  2  37.3 2 1 2  2 37.3 2 1 9 10 3.670 2 12.62 2 2 2 2
2 2 2 2 2  2  37.5 2 1 2  2 37.5 2 2 9 10 2.500 2 8.54 2 1 1 2
2 2 2 2 2  2  38.1 2 1 2  2 38.1 2 2 9 10 2.770 2 3.52 2 2 2 2
2 2 2 1 2  1 MNT 40.1 2 1 2  2 40.1 2 2 9 10 3.270 2 6.36 2 2 2 2
2 2 2 2 2  2  38.6 2 1 2  2 38.6 2 1 9 10 3.090 2 6.14 2 2 2 2
2 2 2 2 2  2  40.3 2 1 2  2 40.3 2 1 9 10 3.440 2 8.77 2 1 2 2
2 2 1 2 2  1 ORAL IRON 37.3 2 2 2 NRFS 2 37.3 2 2 9 10 2.560 2 5.95 2 1 1 2
2 2 2 2 2  2  38.2 2 3 1 PREVIOUS LSCS 2 38.2 2 2 9 10 2.900 2 10.71 2 2 2 2
2 2 2 1 2  1 MNT 39.3 2 3 1 NRFS 2 39.2 2 2 9 10 3.020 2 13.76 2 2 2 2
2 2 2 2 2  2  39.6 2 1 2  2 39.6 2 1 9 10 3.100 2 15.70 2 2 2 2
2 2 2 2 2  2  37.6 2 2 2 NRFS 2 37.6 2 2 9 9 2.480 1 16.00 2 1 1 2
2 2 2 2 2  2  39.6 2 2 2 NRFS 2 39.6 2 1 9 10 3.060 2 6.88 2 2 2 2
2 2 2 2 2  2  39.4 2 1 2  2 39.4 2 2 9 10 3.300 2 2.37 2 2 2 2
1 2 2 2 2  1 ANTIHYPERTENSIVE DRUGS, MGSO4 39.0 2 1 2  2 39.0 2 2 9 10 2.520 2 6.41 2 1 2 2
2 2 2 2 2  2  39.2 2 1 2  2 39.2 2 1 9 10 2.910 2 12.60 2 2 2 2
2 2 1 2 2  1 ORAL IRON 38.6 2 1 2  2 38.6 2 2 9 10 2.500 2 4.21 2 1 1 2
2 2 2 1 2  1 MNT 38.5 2 3 1 PREVIOUS LSCS 2 38.5 2 1 9 10 3.320 2 3.61 2 2 2 2
1 2 2 1 2  1 MNT, ANTIHYPERTENSIVE DRUGS, MGS04 37.1 2 1 2  2 37.1 2 2 9 10 2.070 1 4.27 2 1 1 2
2 2 2 2 2  2  38.6 2 1 2  2 38.6 2 2 9 10 3.040 2 3.96 2 2 2 2
2 2 2 2 2  2  38.1 1 2  2 38.1 2 2 9 10 2.540 2 6.64 2 2 2 2
2 2 2 2 2  2  40.4 2 3 1 FACE PRESENTATION 2 40.4 2 2 9 10 3.620 2 7.84 2 2 2 2
2 2 2 2 2  2  40.5 2 3 1 NRFS 2 40.5 2 1 9 10 3.180 2 15.26 2 2 2 2
2 2 2 2 2  2  40.4 2 3 1 NRFS 2 40.4 2 2 9 10 3.260 2 7.14 2 2 2 2
2 2 2 1 2  1 MNT 40.2 2 3 1 NRFS 2 40.2 2 1 9 10 2.960 2 9.36 2 2 2 2
2 2 2 2 2  2  39.3 2 1 2  2 39.3 2 2 9 10 2.960 2 9.89 2 2 2 2
2 2 1 2 2  1 ORAL IRON 37.6 2 1 2  2 37.6 2 1 9 10 2.570 2 10.90 2 1 2 2
2 2 2 2 2  2  40.2 2 1 2  1 40.2 2 1 9 10 3.720 2 4.39 2 2 2 2
2 2 2 2 2  2  40.1 2 1 2  2 40.1 2 1 9 10 3.030 2 7.73 2 2 2 2
2 2 2 1 2  1 MNT 40.1 2 3 1 PREVIOUS LSCS 2 40.1 2 2 9 10 3.120 2 9.91 2 2 2 2
2 2 2 1 2  1 MNT 38.6 2 3 1 GRADE 2 ABRUPTION 1 38.2 2 2 9 10 2.580 2 3.48 2 1 1 2
2 2 2 2 2  2  38.6 2 1 2  2 38.6 2 1 9 10 2.680 2 7.20 2 2 2 2
2 2 2 2 2  2  37.4 2 2 2 NRFS 2 37.4 2 1 9 10 3.050 2 4.68 2 2 2 2
2 2 1 2 2  1 ORAL IRON 40.3 2 2 2 NRFS 2 40.3 2 2 9 9 2.800 2 6.95 2 2 2 2
2 2 2 1 2  1 MNT 39.4 2 3 1 NRFS 2 39.4 2 1 9 10 2.740 2 5.41 2 2 2 2
2 1 2 1 2  1 MNT 36.0 1 3 1 PREVIOUS LSCS 2 36.0 1 1 8 10 3.160 2 3.21 2 2 2 2
2 1 2 1 2  1 MNT, ANTIHYPERTENSIVE DRUGS 36.2 1 1 2  2 36.2 1 1 9 10 2.790 2 6.41 2 2 2 2
2 2 2 1 2  1 OHA 38.3 2 1 2  2 38.3 2 2 9 10 2.460 1 1.71 2 1 1 2
2 2 2 2 2  2  40.0 2 1 2  2 40.0 2 2 9 10 2.940 2 9.56 2 2 2 2
2 2 2 2 2  2  39.4 2 1 2  2 39.4 2 2 9 10 2.720 2 11.85 2 2 2 2
2 2 1 2 2  1 ORAL IRON 34.4 1 1 2  2 34.4 1 2 9 9 2.300 1 5.38 2 1 2 2
2 2 2 2 2  1 BP MONITORING 37.4 2 1 2  2 37.4 2 2 9 10 2.500 2 9.02 2 2 2 2
2 2 2 1 2  1 MNT 38.1 2 3 1 PREVIOUS LSCS 2 38.1 2 1 9 10 3.320 2 4.21 2 2 2 2
2 2 1 2 2  1 ORAL IRON 39.5 2 1 2  2 39.5 2 2 9 10 3.830 2 5.31 2 2 2 2
2 2 2 2 2  2  37.5 2 3 1 FAILED INDUCTION 2 37.5 2 2 9 10 2.160 1 3.91 2 1 1 2
2 2 2 2 2  2  40.3 2 3 1 PREVIOUS LSCS 2 40.3 2 1 9 10 3.920 2 5.24 2 2 2 2
2 2 2 2 2  2  39.3 2 1 2  2 39.3 2 1 9 10 3.410 2 9.71 2 2 2 2
2 2 2 2 2  2  39.4 2 3 1 NRFS 2 39.4 2 1 9 10 3.180 2 1.86 2 2 2 2
2 2 2 2 2  2  40.2 2 1 2  2 40.2 2 2 9 10 2.970 2 5.33 2 2 2 2
2 1 2 1 2  1 OHA + INSULIN 35.4 1 1 2  2 35.4 1 1 9 10 2.760 2 7.13 2 2 2 2
2 2 2 2 2  2  40.3 2 1 2  2 40.3 2 2 9 10 3.400 2 6.76 2 2 2 2
2 2 1 2 2  1 ORAL IRON 38.0 2 1 2  2 38.0 2 2 9 10 2.670 2 4.25 2 1 2 2
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1 2 2 2 2 2 1 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
1 2 2 1 2 2 2 2 2 2 2 2 1 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
1 1 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 1 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
1 2 2 2 2 2 1 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
2 2 2 2 2 2 2 2 2 2 2 2 2 2  0
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